European Society for Medical Oncology Congress 2023
Format: 1268 videos + 1050 pdfs, size: 385 GB
Course Audience: oncologist
Overview:
20 – 24 Oct 2023, Madrid, Spain
For healthcare professionals, researchers, and those interested in the ever-evolving field of cancer research and care
A comprehensive update covering recent breakthroughs in basic science, translational research, and clinical study results, as well as prevention, screening, and early diagnosis. The programme aimed at helping participants to understand the clinical implications of these advancements, especially in cancer biology, diagnostics, treatments, and educate on the optimal use of new diagnostic tools and therapies for patients with cancer
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Discussion (Video MP4 Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to guide treatment with PET (Video MP4 Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to guide treatment with PET (PDF Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to select the chemotherapy (Video MP4 Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to select the chemotherapy (PDF Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Presentation of case condition (Video MP4 Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Presentation of case condition (PDF Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Preserving fertility in female patients (Video MP4 Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Preserving fertility in female patients (PDF Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass When or when not to irradiate (Video MP4 Format)
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass When or when not to irradiate (PDF Format)
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Current standard of care in adjuvant neoadjuvant therapy of operable NSCLC (Video MP4 Format)
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Current standard of care in adjuvant neoadjuvant therapy of operable NSCLC (PDF Format)
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Discussion (Video MP4 Format)
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Discussion (PDF Format)
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Management of relapse on after perioperative IO (Video MP4 Format)
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Management of relapse on after perioperative IO (PDF Format)
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Predictive biomarkers for adjuvant neoadjuvant IO (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Adjuvant only (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Adjuvant only (PDF Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC First voting (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC First voting (PDF Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant follow by adjuvant (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant follow by adjuvant (PDF Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant only (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant only (PDF Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Perspective from the Chair (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Perspective from the Chair (PDF Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Second voting (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Second voting (PDF Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Welcome and set the scene (Video MP4 Format)
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Welcome and set the scene (PDF Format)
Adrenocortical carcinoma Discussion led by Chair (Video MP4 Format)
Adrenocortical carcinoma Presentation by Expert (Video MP4 Format)
Adrenocortical carcinoma Presentation by Expert (PDF Format)
Advances in our understanding of paraganglioma pheochromocytoma Conclusions and perspectives (Video MP4 Format)
Advances in our understanding of paraganglioma pheochromocytoma Discussion (Video MP4 Format)
Advances in our understanding of paraganglioma pheochromocytoma Discussion (PDF Format)
Advances in our understanding of paraganglioma pheochromocytoma Introduction and scientific background (Video MP4 Format)
Advances in our understanding of paraganglioma pheochromocytoma Introduction and scientific background (PDF Format)
Advances in our understanding of paraganglioma pheochromocytoma Perioperative considerations and management of localised disease (Video MP4 Format)
Advances in our understanding of paraganglioma pheochromocytoma Perioperative considerations and management of localised disease (PDF Format)
Advances in our understanding of paraganglioma pheochromocytoma Targeted radionuclide therapy for advanced disease theranostics (Video MP4 Format)
Advances in our understanding of paraganglioma pheochromocytoma Targeted radionuclide therapy for advanced disease theranostics (PDF Format)
Advances in our understanding of paraganglioma pheochromocytoma The genetics of paraganglioma (PPGL) and implications for testing and screening (Video MP4 Format)
Advances in our understanding of paraganglioma pheochromocytoma The genetics of paraganglioma (PPGL) and implications for testing and screening (PDF Format)
Advances in our understanding of paraganglioma pheochromocytoma The treatment landscape for metastatic PPGL- Are we making progress (Video MP4 Format)
Advances in our understanding of paraganglioma pheochromocytoma The treatment landscape for metastatic PPGL- Are we making progress (PDF Format)
Advances in the management of locally advanced NPC How to transfer results from endemic to non-endemic settings (Video MP4 Format)
Advances in the management of locally advanced NPC How to transfer results from endemic to non-endemic settings (PDF Format)
Advances in the management of locally advanced NPC Induction versus adjuvant chemotherapy in LA-NPC- Deciphering the latest evidence for the practicing oncologist (Video MP4 Format)
Advances in the management of locally advanced NPC Induction versus adjuvant chemotherapy in LA-NPC- Deciphering the latest evidence for the practicing oncologist (PDF Format)
Advances in the management of locally advanced NPC Navigating the undulating landscape of radiotherapy escalation de-escalation in the treatment of LA-NPC (Video MP4 Format)
Advances in the management of locally advanced NPC Navigating the undulating landscape of radiotherapy escalation de-escalation in the treatment of LA-NPC (PDF Format)
Advances in the management of locally advanced NPC Q&A and Discussion (Video MP4 Format)
Advances in the management of locally advanced NPC Q&A and Discussion (PDF Format)
Advances in the management of locally advanced NPC Recent advances in the clinical application of plasma EBV DNA in individualizing treatment of LA-NPC (Video MP4 Format)
Advances in the management of locally advanced NPC Recent advances in the clinical application of plasma EBV DNA in individualizing treatment of LA-NPC (PDF Format)
Advancing strategies for cancer immunotherapy Activation of innate cells through Treg targeting (Video MP4 Format)
Advancing strategies for cancer immunotherapy Activation of innate cells through Treg targeting (PDF Format)
Advancing strategies for cancer immunotherapy CAR-T and TCR-T approaches for solid cancers (Video MP4 Format)
Advancing strategies for cancer immunotherapy CAR-T and TCR-T approaches for solid cancers (PDF Format)
Advancing strategies for cancer immunotherapy Conclusions and perspectives (Video MP4 Format)
Advancing strategies for cancer immunotherapy Conclusions and perspectives (PDF Format)
Advancing strategies for cancer immunotherapy Discussion (Video MP4 Format)
Advancing strategies for cancer immunotherapy Discussion (PDF Format)
Advancing strategies for cancer immunotherapy Intra-tumoural immunotherapy (Video MP4 Format)
Advancing strategies for cancer immunotherapy Intra-tumoural immunotherapy (PDF Format)
Advancing strategies for cancer immunotherapy Introduction and scientific background (Video MP4 Format)
Advancing strategies for cancer immunotherapy Introduction and scientific background (PDF Format)
Advancing strategies for cancer immunotherapy New approaches in cancer vaccines (Video MP4 Format)
Advancing strategies for cancer immunotherapy New approaches in cancer vaccines (PDF Format)
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Discussion led by Chair (Video MP4 Format)
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Discussion led by Chair (PDF Format)
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Presentation by Expert (Video MP4 Format)
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Presentation by Expert (PDF Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy First voting (Video MP4 Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy First voting (PDF Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy No (Video MP4 Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy No (PDF Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Perspective from the Chair (Video MP4 Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Perspective from the Chair (PDF Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Second voting (Video MP4 Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Second voting (PDF Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Welcome and set the scene (Video MP4 Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Welcome and set the scene (PDF Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Yes (Video MP4 Format)
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Yes (PDF Format)
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Discussion led by Chair (Video MP4 Format)
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Discussion led by Chair (PDF Format)
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Presentation by Expert (Video MP4 Format)
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Presentation by Expert (PDF Format)
Antibody drug conjugates- Current data and future role in drug development Discussion led by Chair (Video MP4 Format)
Antibody drug conjugates- Current data and future role in drug development Presentation by Expert (Video MP4 Format)
Antibody drug conjugates- Current data and future role in drug development Presentation by Expert (PDF Format)
Artificial Intelligence in prognostication AI for breast cancer prognostication (Video MP4 Format)
Artificial Intelligence in prognostication AI for breast cancer prognostication (PDF Format)
Artificial Intelligence in prognostication Biomarkers of response to drugs and radiotherapy (Video MP4 Format)
Artificial Intelligence in prognostication Biomarkers of response to drugs and radiotherapy (PDF Format)
Artificial Intelligence in prognostication Digital pathology for immuno-oncology (Video MP4 Format)
Artificial Intelligence in prognostication Digital pathology for immuno-oncology (PDF Format)
Artificial Intelligence in prognostication Q&A and Discussion (Video MP4 Format)
Artificial Intelligence in prognostication Q&A and Discussion (PDF Format)
Astellas Pharma Europe Ltd – Putting the patient first Closing remarks (Video MP4 Format)
Astellas Pharma Europe Ltd – Putting the patient first Maximising quality of life- Holistic approaches in the management of patients with mHSPC (Video MP4 Format)
Astellas Pharma Europe Ltd – Putting the patient first Reinforcing standard of care- The benefits of early treatment intensification in patients with mHSPC (Video MP4 Format)
Astellas Pharma Europe Ltd – Putting the patient first The importance of first-line treatment choice in patients with mHSPC (Video MP4 Format)
Astellas Pharma Europe Ltd – Putting the patient first Welcome and introduction (Video MP4 Format)
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Clinical experiences with first-line treatment of LA_mUC (Video MP4 Format)
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC First-line therapy for patients with LA_mUC- The transformation (Video MP4 Format)
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Housekeeping and introductions (Video MP4 Format)
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Overview of current trials investigating first-line treatment of LA_mUC (Video MP4 Format)
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Panel discussion (Video MP4 Format)
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Summary and close (Video MP4 Format)
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Antibody-Drug Conjugates for HR-Positive Breast Cancer- Where Are We Today- (Video MP4 Format)
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Audience Q&A (Video MP4 Format)
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Concluding Remarks (Video MP4 Format)
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer New Antibody-Drug Conjugates on the Horizon (Video MP4 Format)
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Next-Generation Antibody-Drug Conjugates in Practice- A Case-Based Discussion (Video MP4 Format)
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Welcome and Introduction (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Closing Remarks (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Impact From Within- Patient Advocacy and the Voices That Bring Progress (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Making It Stick- Implementing the Advances in Precision Oncology into Clinical Practice (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Open Panel Audience Q&A (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives The Big Bang of Precision Oncology- Creating Milestones in Medicine (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives The Voice That Matters – A Patient Perspective (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Theory to Reality- Overcoming Challenges and Raising the Value of Precision Oncology (Video MP4 Format)
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Welcome (Video MP4 Format)
Biomarkers in metastatic colorectal cancer Biomarkers in 2023- What, how and when to test (Video MP4 Format)
Biomarkers in metastatic colorectal cancer Biomarkers in 2023- What, how and when to test (PDF Format)
Biomarkers in metastatic colorectal cancer Biomarkers in the near future- What to expect (Video MP4 Format)
Biomarkers in metastatic colorectal cancer Biomarkers in the near future- What to expect (PDF Format)
Biomarkers in metastatic colorectal cancer Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK) (Video MP4 Format)
Biomarkers in metastatic colorectal cancer Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK) (PDF Format)
Biomarkers in metastatic colorectal cancer Q&A and Discussion (Video MP4 Format)
Biomarkers in metastatic colorectal cancer Q&A and Discussion (PDF Format)
Bladder preservation strategies Discussion (Video MP4 Format)
Bladder preservation strategies Discussion (PDF Format)
Bladder preservation strategies Organ preservation for refractory NMIBC- A surgeon’s perspective (Video MP4 Format)
Bladder preservation strategies Organ preservation for refractory NMIBC- A surgeon’s perspective (PDF Format)
Bladder preservation strategies Presentation of case condition- Non-muscle invasive bladder cancer (NMIBC) progressing to MIBC (Video MP4 Format)
Bladder preservation strategies Presentation of case condition- Non-muscle invasive bladder cancer (NMIBC) progressing to MIBC (PDF Format)
Bladder preservation strategies Radiotherapy in bladder preservation (Video MP4 Format)
Bladder preservation strategies Radiotherapy in bladder preservation (PDF Format)
Bladder preservation strategies The role of systemic therapy in bladder preservation (Video MP4 Format)
Bladder preservation strategies The role of systemic therapy in bladder preservation (PDF Format)
Boehringer Ingelheim – Rethinking Cancer Therapies Improving HER2 Targeting in NSCLC with Selective TKI (Video MP4 Format)
Boehringer Ingelheim – Rethinking Cancer Therapies Panel Discussion and Audience Q&A, Key Takeaways and Closing Remarks (Video MP4 Format)
Boehringer Ingelheim – Rethinking Cancer Therapies Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma (Video MP4 Format)
Boehringer Ingelheim – Rethinking Cancer Therapies T-cell Engagers- Fighting Solid Tumors from Within (Video MP4 Format)
Boehringer Ingelheim – Rethinking Cancer Therapies Welcome and Introduction of Agenda and Speakers (Video MP4 Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Discussion (Video MP4 Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Discussion (PDF Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice (Video MP4 Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice (PDF Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Should effectiveness data be taken into consideration for drug appraisal by regulatory authorities (Video MP4 Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Should effectiveness data be taken into consideration for drug appraisal by regulatory authorities (PDF Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Under which circumstances could effectiveness data be used for clinical guidelines (Video MP4 Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Under which circumstances could effectiveness data be used for clinical guidelines (PDF Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which adaptations in trials and daily practice could bridge the E-E gap (Video MP4 Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which adaptations in trials and daily practice could bridge the E-E gap (PDF Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which factors can cause an E-E gap (Video MP4 Format)
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which factors can cause an E-E gap (PDF Format)
Bringing together thyroid cancer and neuroendocrine tumours Discussion (Video MP4 Format)
Bringing together thyroid cancer and neuroendocrine tumours Discussion (PDF Format)
Bringing together thyroid cancer and neuroendocrine tumours Future directions on targeted agents and beyond in thyroid and neuroendocrine tumours (Video MP4 Format)
Bringing together thyroid cancer and neuroendocrine tumours Future directions on targeted agents and beyond in thyroid and neuroendocrine tumours (PDF Format)
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced neuroendocrine tumours (PDF Format)
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced neuroendocrine tumours (Video MP4 Format)
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced thyroid cancer (Video MP4 Format)
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced thyroid cancer (PDF Format)
Bringing together thyroid cancer and neuroendocrine tumours What we could learn from each tumour type to improve the management of both (Video MP4 Format)
Bringing together thyroid cancer and neuroendocrine tumours What we could learn from each tumour type to improve the management of both (PDF Format)
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Advances in Immuno-Oncology for the Treatment of Colorectal Cancer (Video MP4 Format)
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Immuno-Oncology Landscape for GI Cancers- Perspectives on Current Practices and Recent Advances (Video MP4 Format)
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Immunotherapeutic Advances in the Treatment of Esophageal Cancer (Video MP4 Format)
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Roundtable Case Discussion, Q&A (Video MP4 Format)
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Update on Immuno-Oncology for the Treatment of Gastric Cancer (Video MP4 Format)
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Current and Emerging Neoadjuvant Treatment Options for Resectable Melanoma (Video MP4 Format)
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Evidence-Based Considerations for the First-Line Treatment of Metastatic Melanoma (Video MP4 Format)
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Navigating the Adjuvant Setting- Who, When, and What- (Video MP4 Format)
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Panel Discussion- Factors Impacting Treatment Selection for Resectable Melanoma (Video MP4 Format)
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Summary and Close (Video MP4 Format)
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Welcome and Introduction (Video MP4 Format)
Building an academic cell therapy programme Clinical requirements (Video MP4 Format)
Building an academic cell therapy programme Clinical requirements (PDF Format)
Building an academic cell therapy programme Lab requirements and translational opportunities (Video MP4 Format)
Building an academic cell therapy programme Lab requirements and translational opportunities (PDF Format)
Building an academic cell therapy programme Presentation of case condition (Video MP4 Format)
Building an academic cell therapy programme Presentation of case condition (PDF Format)
Building an academic cell therapy programme Q&A and Discussion (Video MP4 Format)
Building an academic cell therapy programme Q&A and Discussion (PDF Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients First voting (Video MP4 Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients First voting (PDF Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients No (Video MP4 Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients No (PDF Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Perspective from the Chair (Video MP4 Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Perspective from the Chair (PDF Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Second voting (Video MP4 Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Second voting (PDF Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Welcome and set the scene (Video MP4 Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Welcome and set the scene (PDF Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Yes (Video MP4 Format)
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Yes (PDF Format)
Cancer-related central and peripheral neuropathy Conclusions and perspectives (Video MP4 Format)
Cancer-related central and peripheral neuropathy Conclusions and perspectives (PDF Format)
Cancer-related central and peripheral neuropathy Discussion (Video MP4 Format)
Cancer-related central and peripheral neuropathy Discussion (PDF Format)
Cancer-related central and peripheral neuropathy Introduction and scientific background (Video MP4 Format)
Cancer-related central and peripheral neuropathy Introduction and scientific background (PDF Format)
Cancer-related central and peripheral neuropathy Preventive strategies for chemotherapy-induced peripheral neuropathy (CIPN) (Video MP4 Format)
Cancer-related central and peripheral neuropathy Preventive strategies for chemotherapy-induced peripheral neuropathy (CIPN) (PDF Format)
Cancer-related central and peripheral neuropathy Unmet needs (Video MP4 Format)
Cancer-related central and peripheral neuropathy Unmet needs (PDF Format)
Challenges in the management of Waldenstr”m’s macroglobulinemia Discussion led by Chair (Video MP4 Format)
Challenges in the management of Waldenstr”m’s macroglobulinemia Presentation by Expert (Video MP4 Format)
Challenges in the management of Waldenstr”m’s macroglobulinemia Presentation by Expert (PDF Format)
Challenging common problems in neuro-oncology Discussion (Video MP4 Format)
Challenging common problems in neuro-oncology Presentation of case- Low-grade glioma (Video MP4 Format)
Challenging common problems in neuro-oncology Presentation of case- Low-grade glioma (PDF Format)
Challenging common problems in neuro-oncology Radiotherapy for low grade gliomas with and without mutations- Wait or treat (Video MP4 Format)
Challenging common problems in neuro-oncology Radiotherapy for low grade gliomas with and without mutations- Wait or treat (PDF Format)
Challenging common problems in neuro-oncology The optimal radiochemotherapeutic combination for low grade gliomas- Lessons from trials (Video MP4 Format)
Challenging common problems in neuro-oncology Upfront and salvage surgery for low grade gliomas (Video MP4 Format)
Challenging common problems in neuro-oncology Upfront and salvage surgery for low grade gliomas (PDF Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Conclusions and perspectives (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Discussion (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Discussion (PDF Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Introduction and scientific background (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Introduction and scientific background (PDF Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Investigator perspective (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Investigator perspective (PDF Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Patient advocacy perspective (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Patient advocacy perspective (PDF Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Pharmaceutical industry perspective (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Pharmaceutical industry perspective (PDF Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Project Optimus update (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Project Optimus update (PDF Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Regulatory perspective- FDA (Video MP4 Format)
Challenging the status quo of early phase clinical trial design- Project Optimus Regulatory perspective- FDA (PDF Format)
Checkpoint inhibition and beyond- New approaches in advanced gastric oesophageal cancer Discussion led by Chair (Video MP4 Format)
Checkpoint inhibition and beyond- New approaches in advanced gastric oesophageal cancer Presentation by Expert (Video MP4 Format)
Checkpoint inhibition and beyond- New approaches in advanced gastric oesophageal cancer Presentation by Expert (PDF Format)
Circulating tumour DNA A perfect fit Conclusions and perspectives (Video MP4 Format)
Circulating tumour DNA A perfect fit Conclusions and perspectives (PDF Format)
Circulating tumour DNA A perfect fit ctDNA assessment- How and when (Video MP4 Format)
Circulating tumour DNA A perfect fit ctDNA assessment- How and when (PDF Format)
Circulating tumour DNA A perfect fit ctDNA clearance- Surrogacy for cure and organ-sparing approaches (Video MP4 Format)
Circulating tumour DNA A perfect fit ctDNA clearance- Surrogacy for cure and organ-sparing approaches (PDF Format)
Circulating tumour DNA A perfect fit ctDNA in early-stage CRC- Tailoring the adjuvant therapy (Video MP4 Format)
Circulating tumour DNA A perfect fit ctDNA in early-stage CRC- Tailoring the adjuvant therapy (PDF Format)
Circulating tumour DNA A perfect fit ctDNA in mCRC- Monitoring response and guiding treatment (Video MP4 Format)
Circulating tumour DNA A perfect fit ctDNA in mCRC- Monitoring response and guiding treatment (PDF Format)
Circulating tumour DNA A perfect fit Discussion (Video MP4 Format)
Circulating tumour DNA A perfect fit Discussion (PDF Format)
Circulating tumour DNA A perfect fit Introduction and scientific background (Video MP4 Format)
Circulating tumour DNA A perfect fit Introduction and scientific background (PDF Format)
Climate Change Task Force – How to build more sustainable and environment-friendly oncology care Rationale drug prescribing to reduce environmental impact (PDF Format)
Controversies in early stage triple negative breast cancer Conclusions and perspectives (Video MP4 Format)
Controversies in early stage triple negative breast cancer Discussion (Video MP4 Format)
Controversies in early stage triple negative breast cancer Discussion (PDF Format)
Controversies in early stage triple negative breast cancer Individualisation of adjuvant therapy in TNBC- Who gets what (Video MP4 Format)
Controversies in early stage triple negative breast cancer Individualisation of adjuvant therapy in TNBC- Who gets what (PDF Format)
Controversies in early stage triple negative breast cancer Introduction and scientific background (Video MP4 Format)
Controversies in early stage triple negative breast cancer Introduction and scientific background (PDF Format)
Controversies in early stage triple negative breast cancer Optimal neo-adjuvant therapy in TNBC- Does one size fit all (Video MP4 Format)
Controversies in early stage triple negative breast cancer Optimal neo-adjuvant therapy in TNBC- Does one size fit all (PDF Format)
Controversies in early stage triple negative breast cancer Role of biomarkers ctDNA monitoring in therapy decisions (Video MP4 Format)
Controversies in early stage triple negative breast cancer Role of biomarkers ctDNA monitoring in therapy decisions (PDF Format)
Controversies in early stage triple negative breast cancer What to do with stage 1 TNBC- Can we deescalate systemic therapy (Video MP4 Format)
Controversies in early stage triple negative breast cancer What to do with stage 1 TNBC- Can we deescalate systemic therapy (PDF Format)
Current issues in primary prevention and screening to block the onset or development of cancer Commercial drivers of cancer medicines and non-pharmaceutical technologies in cancer care (Video MP4 Format)
Current issues in primary prevention and screening to block the onset or development of cancer Commercial drivers of cancer medicines and non-pharmaceutical technologies in cancer care (PDF Format)
Current issues in primary prevention and screening to block the onset or development of cancer False dichotomies and going beyond screening (Video MP4 Format)
Current issues in primary prevention and screening to block the onset or development of cancer False dichotomies and going beyond screening (PDF Format)
Current issues in primary prevention and screening to block the onset or development of cancer Processed meat, sugar, exercise- Prevention opportunities for oncologists (Video MP4 Format)
Current issues in primary prevention and screening to block the onset or development of cancer Processed meat, sugar, exercise- Prevention opportunities for oncologists (PDF Format)
Current issues in primary prevention and screening to block the onset or development of cancer Q&A and Discussion (Video MP4 Format)
Current issues in primary prevention and screening to block the onset or development of cancer Q&A and Discussion (PDF Format)
Current issues in primary prevention and screening to block the onset or development of cancer Structural and behavioural interventions (Video MP4 Format)
Current issues in primary prevention and screening to block the onset or development of cancer Structural and behavioural interventions (PDF Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Conclusions and perspectives (Video MP4 Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Discussion (Video MP4 Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Discussion (PDF Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Immunotherapy (Video MP4 Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Immunotherapy (PDF Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Introduction and scientific background (Video MP4 Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Introduction and scientific background (PDF Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Methylation profiling- Hype or progress (Video MP4 Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Methylation profiling- Hype or progress (PDF Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours New treatment targets- From bench to bedside (Video MP4 Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours New treatment targets- From bench to bedside (PDF Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Opening the blood-brain barrier (BBB) (Video MP4 Format)
Cutting edge diagnostics and innovation in the treatment of brain tumours Opening the blood-brain barrier (BBB) (PDF Format)
Diffuse large B-cell lymphoma First-line therapy (Video MP4 Format)
Diffuse large B-cell lymphoma First-line therapy (PDF Format)
Diffuse large B-cell lymphoma Molecular classification (Video MP4 Format)
Diffuse large B-cell lymphoma Molecular classification (PDF Format)
Diffuse large B-cell lymphoma Q&A and Discussion (Video MP4 Format)
Diffuse large B-cell lymphoma Q&A and Discussion (PDF Format)
Diffuse large B-cell lymphoma Therapy at relapse (Video MP4 Format)
Diffuse large B-cell lymphoma Therapy at relapse (PDF Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Discussion (Video MP4 Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Discussion (PDF Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Evidence from trials- Summary of a fantastic decade (Video MP4 Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Evidence from trials- Summary of a fantastic decade (PDF Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit How to best integrate biology (Video MP4 Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit How to best integrate biology (PDF Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Next generation imaging- How does it change the evidence seen in trials (Video MP4 Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Next generation imaging- How does it change the evidence seen in trials (PDF Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Tolerance and long-term side-effects (Video MP4 Format)
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Tolerance and long-term side-effects (PDF Format)
Do we enter a new era of oncology AI-based therapeutic algorithms in oncology (Video MP4 Format)
Do we enter a new era of oncology AI-based therapeutic algorithms in oncology (PDF Format)
Do we enter a new era of oncology Q&A and Discussion (Video MP4 Format)
Do we enter a new era of oncology Q&A and Discussion (PDF Format)
Do we enter a new era of oncology Wearable medical devices in oncology (Video MP4 Format)
Do we enter a new era of oncology Wearable medical devices in oncology (PDF Format)
Do we enter a new era of oncology What will the European Health Data Space bring us (Video MP4 Format)
Do we enter a new era of oncology What will the European Health Data Space bring us (PDF Format)
Do we enter a new era of oncology Where are we in Oncology in relation to developments in digital health, big data, artificial intelligence (Video MP4 Format)
Do we enter a new era of oncology Where are we in Oncology in relation to developments in digital health, big data, artificial intelligence (PDF Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions A dermatologist’s perspective- Secondary prevention and risk stratifications strategies (Video MP4 Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions A dermatologist’s perspective- Secondary prevention and risk stratifications strategies (PDF Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions A pathologist’s perspective- What to look for and how to report it (Video MP4 Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions A pathologist’s perspective- What to look for and how to report it (PDF Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Discussion (Video MP4 Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Discussion (PDF Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A medical oncologist’s perspective (Video MP4 Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A medical oncologist’s perspective (PDF Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A surgeon’s perspective (Video MP4 Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A surgeon’s perspective (PDF Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Presentation of case condition (Video MP4 Format)
Early-stage (II III) melanoma- Risk stratification and treatment decisions Presentation of case condition (PDF Format)
East meets West in the management of head and neck cancer- Learning from each other Discussion led by Chair (Video MP4 Format)
East meets West in the management of head and neck cancer- Learning from each other Presentation by Expert (Video MP4 Format)
East meets West in the management of head and neck cancer- Learning from each other Presentation by Expert (PDF Format)
Elucidating cancer biology, and transforming cancer care, through academic drug development Elucidating cancer biology, and transforming cancer care, through academic drug development (Video MP4 Format)
Elucidating cancer biology, and transforming cancer care, through academic drug development Elucidating cancer biology, and transforming cancer care, through academic drug development (PDF Format)
Elucidating cancer biology, and transforming cancer care, through academic drug development Introduction by the Chair (Video MP4 Format)
Elucidating cancer biology, and transforming cancer care, through academic drug development Introduction by the Chair (PDF Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases AYA oncology- The importance of research, with a focus on patients with melanoma (Video MP4 Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases AYA oncology- The importance of research, with a focus on patients with melanoma (PDF Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Discussion (Video MP4 Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Discussion (PDF Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Introduction (Video MP4 Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Introduction (PDF Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Setting priorities for AYA patients with sarcoma (Video MP4 Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Setting priorities for AYA patients with sarcoma (PDF Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Short- and long-term side effects in AYA patients, with a focus on patients with breast cancer (Video MP4 Format)
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Short- and long-term side effects in AYA patients, with a focus on patients with breast cancer (PDF Format)
ESMO ASCO Global Curriculum Medical oncology Training Development and update of the ESMO ASCO Global Curriculum- Why and how (Video MP4 Format)
ESMO ASCO Global Curriculum Medical oncology Training Development and update of the ESMO ASCO Global Curriculum- Why and how (PDF Format)
ESMO ASCO Global Curriculum Medical oncology Training Discussion and Q&A (Video MP4 Format)
ESMO ASCO Global Curriculum Medical oncology Training Discussion and Q&A (PDF Format)
ESMO ASCO Global Curriculum Medical oncology Training Integrating global standards in medical oncology training- The perspective of the trainee (Video MP4 Format)
ESMO ASCO Global Curriculum Medical oncology Training Integrating global standards in medical oncology training- The perspective of the trainee (PDF Format)
ESMO ASCO Global Curriculum Medical oncology Training Introduction (Video MP4 Format)
ESMO ASCO Global Curriculum Medical oncology Training Introduction (PDF Format)
ESMO ASCO Global Curriculum Medical oncology Training Optimizing learning in a fast-paced training environment- The perspective of the trainee (Video MP4 Format)
ESMO ASCO Global Curriculum Medical oncology Training Optimizing learning in a fast-paced training environment- The perspective of the trainee (PDF Format)
ESMO ASCO Global Curriculum Medical oncology Training The role of the Global Curriculum in the era of digital health and artificial intelligence (Video MP4 Format)
ESMO ASCO Global Curriculum Medical oncology Training The role of the Global Curriculum in the era of digital health and artificial intelligence (PDF Format)
ESMO ASCO Global Curriculum Medical oncology Training Using the ESMO ASCO Global Curriculum and Log Book to improve educational content (Video MP4 Format)
ESMO ASCO Global Curriculum Medical oncology Training Using the ESMO ASCO Global Curriculum and Log Book to improve educational content (PDF Format)
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer case presentation (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer case presentation (PDF Format)
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer discussion (PDF Format)
ESMO Clinical Practice Guidelines 1 Early breast cancer case discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Early breast cancer case discussion (PDF Format)
ESMO Clinical Practice Guidelines 1 Early breast cancer case presentation (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Early breast cancer case presentation (PDF Format)
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC case presentation (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC case presentation (PDF Format)
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC discussion (PDF Format)
ESMO Clinical Practice Guidelines 1 Q&A 1 (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Q&A 1 (PDF Format)
ESMO Clinical Practice Guidelines 1 Q&A 2 (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Q&A 2 (PDF Format)
ESMO Clinical Practice Guidelines 1 Q&A and Discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 1 Q&A and Discussion (PDF Format)
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC case presentation (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC case presentation (PDF Format)
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC discussion (PDF Format)
ESMO Clinical Practice Guidelines 2 Prostate cancer case presentation (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Prostate cancer case presentation (PDF Format)
ESMO Clinical Practice Guidelines 2 Prostate cancer discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Prostate cancer discussion (PDF Format)
ESMO Clinical Practice Guidelines 2 Q&A 1 (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Q&A 1 (PDF Format)
ESMO Clinical Practice Guidelines 2 Q&A 2 (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Q&A 2 (PDF Format)
ESMO Clinical Practice Guidelines 2 Q&A and Discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Q&A and Discussion (PDF Format)
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck case presentation (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck case presentation (PDF Format)
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck discussion (Video MP4 Format)
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck discussion (PDF Format)
ESMO Colloquium supported by Daiichi Sankyo Antibody-drug conjugates- Novel combinations with precision therapeutics and the quest for biomarkers (Video MP4 Format)
ESMO Colloquium supported by Daiichi Sankyo Concluding remarks (Video MP4 Format)
ESMO Colloquium supported by Daiichi Sankyo Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients (Video MP4 Format)
ESMO Colloquium supported by Daiichi Sankyo Improving the safety profiles of ADCs- Early detection and optimal management of toxicities (Video MP4 Format)
ESMO Colloquium supported by Daiichi Sankyo Q&A and discussion (Video MP4 Format)
ESMO Colloquium supported by Daiichi Sankyo Welcome and introduction (Video MP4 Format)
ESMO Colloquium supported by Eisai Europe Ltd Concluding remarks (Video MP4 Format)
ESMO Colloquium supported by Eisai Europe Ltd Current and emerging clinicopathologic and molecular prognostic schemes for patients with advanced renal cell carcinoma (Video MP4 Format)
ESMO Colloquium supported by Eisai Europe Ltd Do all patients need combination therapy- De-escalation and patient selection (Video MP4 Format)
ESMO Colloquium supported by Eisai Europe Ltd Q&A and discussion (Video MP4 Format)
ESMO Colloquium supported by Eisai Europe Ltd Research insights in enhancing treatment efficacy- Escalation, sequencing and prediction (Video MP4 Format)
ESMO Colloquium supported by Eisai Europe Ltd State-of-the-art combination therapies for patients with advanced RCC (Video MP4 Format)
ESMO Colloquium supported by Eisai Europe Ltd Welcome and introduction (Video MP4 Format)
ESMO Colloquium supported by Eli Lilly and Company Concluding remarks (Video MP4 Format)
ESMO Colloquium supported by Eli Lilly and Company Q&A and discussion (Video MP4 Format)
ESMO Colloquium supported by Eli Lilly and Company Targeting molecular aberrations beyond EGFR, ALK- Clinical evidence for efficacy and ongoing research (Video MP4 Format)
ESMO Colloquium supported by Eli Lilly and Company The availability of molecular testing in Europe and its implications for state-of-the-art care for patients with lung cancer (Video MP4 Format)
ESMO Colloquium supported by Eli Lilly and Company The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer- Science, implementation and timing (Video MP4 Format)
ESMO Colloquium supported by Eli Lilly and Company Welcome and introduction (Video MP4 Format)
ESMO Designated Centres Conclusion and next steps (Video MP4 Format)
ESMO Designated Centres Conclusion and next steps (PDF Format)
ESMO Designated Centres Designated Centres Awards (Video MP4 Format)
ESMO Designated Centres Designated Centres Awards (PDF Format)
ESMO Designated Centres Designated centres virtual visits pilot (Video MP4 Format)
ESMO Designated Centres Designated centres virtual visits pilot (PDF Format)
ESMO Designated Centres Importance of integration of palliative care into mainstream oncology (Video MP4 Format)
ESMO Designated Centres Importance of integration of palliative care into mainstream oncology (PDF Format)
ESMO Designated Centres Introduction (Video MP4 Format)
ESMO Designated Centres Introduction (PDF Format)
ESMO Designated Centres MyPath update and introduction to the JANE network (Video MP4 Format)
ESMO Designated Centres MyPath update and introduction to the JANE network (PDF Format)
ESMO Designated Centres Q&A (Video MP4 Format)
ESMO Designated Centres Q&A (PDF Format)
ESMO Designated Centres Symptom screening with Targeted Early Palliative care (STEP) intervention (Video MP4 Format)
ESMO Designated Centres Symptom screening with Targeted Early Palliative care (STEP) intervention (PDF Format)
ESMO Guideline updates on supportive and palliative care Anxiety, depression and insomnia (Video MP4 Format)
ESMO Guideline updates on supportive and palliative care Anxiety, depression and insomnia (PDF Format)
ESMO Guideline updates on supportive and palliative care Prognostication in advanced cancer- Navigating the uncertainty (Video MP4 Format)
ESMO Guideline updates on supportive and palliative care Prognostication in advanced cancer- Navigating the uncertainty (PDF Format)
ESMO Guideline updates on supportive and palliative care Q&A and Discussion (Video MP4 Format)
ESMO Guideline updates on supportive and palliative care Q&A and Discussion (PDF Format)
ESMO-MCBS 2023 revolution A guide through the new ESMO-MCBS v2.0 (Video MP4 Format)
ESMO-MCBS 2023 revolution A guide through the new ESMO-MCBS v2.0 (PDF Format)
ESMO-MCBS 2023 revolution Conclusions and perspectives, discussion and Q&A (Video MP4 Format)
ESMO-MCBS 2023 revolution Conclusions and perspectives, discussion and Q&A (PDF Format)
ESMO-MCBS 2023 revolution ESMO-Magnitude of Clinical Scale for Haematological Malignancies (ESMO-MCBS-H) (Video MP4 Format)
ESMO-MCBS 2023 revolution ESMO-Magnitude of Clinical Scale for Haematological Malignancies (ESMO-MCBS-H) (PDF Format)
ESMO-MCBS 2023 revolution Introduction (Video MP4 Format)
ESMO-MCBS 2023 revolution Introduction (PDF Format)
ESMO-MCBS 2023 revolution Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI) (Video MP4 Format)
ESMO-MCBS 2023 revolution Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI) (PDF Format)
ESMO-WHO review of innovation in cancer therapeutics Evaluating innovative products in breast cancer Characteristics, impact and market share (Video MP4 Format)
ESMO-WHO review of innovation in cancer therapeutics Evaluating innovative products in breast cancer Characteristics, impact and market share (PDF Format)
ESMO-WHO review of innovation in cancer therapeutics Horizon scanning of emerging therapeutics in the next decade What does the future hold (Video MP4 Format)
ESMO-WHO review of innovation in cancer therapeutics Horizon scanning of emerging therapeutics in the next decade What does the future hold (PDF Format)
ESMO-WHO review of innovation in cancer therapeutics Innovation in the EU Cancer Mission Delivering solutions (Video MP4 Format)
ESMO-WHO review of innovation in cancer therapeutics Innovation in the EU Cancer Mission Delivering solutions (PDF Format)
ESMO-WHO review of innovation in cancer therapeutics Introduction (Video MP4 Format)
ESMO-WHO review of innovation in cancer therapeutics Introduction (PDF Format)
ESMO-WHO review of innovation in cancer therapeutics Panel Discussion (Video MP4 Format)
ESMO-WHO review of innovation in cancer therapeutics Q&A and closing remarks (Video MP4 Format)
ESMO-WHO review of innovation in cancer therapeutics Q&A and closing remarks (PDF Format)
Fight the enemy as soon as possible Current systemic treatment of locally advanced colon cancer (Video MP4 Format)
Fight the enemy as soon as possible Current systemic treatment of locally advanced colon cancer (PDF Format)
Fight the enemy as soon as possible Future directions neoadjuvant versus adjuvant (Video MP4 Format)
Fight the enemy as soon as possible Future directions neoadjuvant versus adjuvant (PDF Format)
Fight the enemy as soon as possible How do we optimise imaging (Video MP4 Format)
Fight the enemy as soon as possible How do we optimise imaging (PDF Format)
Fight the enemy as soon as possible Q&A and Discussion (Video MP4 Format)
Fight the enemy as soon as possible Q&A and Discussion (PDF Format)
Fight the enemy as soon as possible Screening programmes 20 years later Lessons learned and how to move on (Video MP4 Format)
Fight the enemy as soon as possible Screening programmes 20 years later Lessons learned and how to move on (PDF Format)
final_programme_esmo2023 (PDF Format)
Finding the positive in triple negative breast cancer Conclusions and perspectives (Video MP4 Format)
Finding the positive in triple negative breast cancer Conclusions and perspectives (PDF Format)
Finding the positive in triple negative breast cancer Discussion (Video MP4 Format)
Finding the positive in triple negative breast cancer Discussion (PDF Format)
Finding the positive in triple negative breast cancer Emerging targets in TNBC (Video MP4 Format)
Finding the positive in triple negative breast cancer Emerging targets in TNBC (PDF Format)
Finding the positive in triple negative breast cancer Integrative multiomics analysis to dissect TNBC (Video MP4 Format)
Finding the positive in triple negative breast cancer Integrative multiomics analysis to dissect TNBC (PDF Format)
Finding the positive in triple negative breast cancer Introduction and scientific background (Video MP4 Format)
Finding the positive in triple negative breast cancer Introduction and scientific background (PDF Format)
Finding the positive in triple negative breast cancer Predicting response or resistance to IO (Video MP4 Format)
Finding the positive in triple negative breast cancer Predicting response or resistance to IO (PDF Format)
Finding the positive in triple negative breast cancer Targeting DNA damage response (Video MP4 Format)
Finding the positive in triple negative breast cancer Targeting DNA damage response (PDF Format)
First-line therapy in advanced melanoma- What is my preferred choice I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons why (Video MP4 Format)
First-line therapy in advanced melanoma- What is my preferred choice I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons why (PDF Format)
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is combined immunotherapy with PD1+CTLA-4, and these are the reasons why (Video MP4 Format)
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is combined immunotherapy with PD1+CTLA-4, and these are the reasons why (PDF Format)
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is PD-1 monotherapy, and these are the reasons why (Video MP4 Format)
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is PD-1 monotherapy, and these are the reasons why (PDF Format)
First-line therapy in advanced melanoma- What is my preferred choice Q&A and Discussion (Video MP4 Format)
First-line therapy in advanced melanoma- What is my preferred choice Q&A and Discussion (PDF Format)
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Discussion led by Chair (Video MP4 Format)
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Discussion led by Chair (PDF Format)
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert ALK (Video MP4 Format)
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert ALK (PDF Format)
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert EGFR (Video MP4 Format)
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert EGFR (PDF Format)
Genetic predisposition in patients with sarcoma Discussion (Video MP4 Format)
Genetic predisposition in patients with sarcoma Discussion (PDF Format)
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A medical oncologist’s perspective (Video MP4 Format)
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A medical oncologist’s perspective (PDF Format)
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A surgeon’s perspective (Video MP4 Format)
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A surgeon’s perspective (PDF Format)
Genetic predisposition in patients with sarcoma How to treat sarcoma patients with a hereditary predisposition- A radiation oncologist’s perspective (Video MP4 Format)
Genetic predisposition in patients with sarcoma How to treat sarcoma patients with a hereditary predisposition- A radiation oncologist’s perspective (PDF Format)
Genetic predisposition in patients with sarcoma How to use radiology in patients with hereditary syndromes (Video MP4 Format)
Genetic predisposition in patients with sarcoma How to use radiology in patients with hereditary syndromes (PDF Format)
Genetic predisposition in patients with sarcoma When and why to test a patient with sarcoma for hereditary predisposition (Video MP4 Format)
Genetic predisposition in patients with sarcoma When and why to test a patient with sarcoma for hereditary predisposition (PDF Format)
Gilead Sciences Europe Ltd – Lines of progress Audience Q&A (Video MP4 Format)
Gilead Sciences Europe Ltd – Lines of progress Expanding possibilities in HR+_HER2- mBC (Video MP4 Format)
Gilead Sciences Europe Ltd – Lines of progress Improving outcomes for patients with metastatic TNBC (Video MP4 Format)
Gilead Sciences Europe Ltd – Lines of progress Metastatic Breast Cancer- A journey of progress through innovations (Video MP4 Format)
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Expanding opportunities in patients with metastatic NSCLC (Video MP4 Format)
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Improving the lives of patients with triple-negative and HR+_HER2- metastatic breast cancer (Video MP4 Format)
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Q&A and closing remarks (Video MP4 Format)
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Unlocking the potential for the treatment of metastatic urothelial cancer (Video MP4 Format)
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Welcome and introduction- ADCs – A journey across time (Video MP4 Format)
GSK – The breakthrough era in endometrial cancer treatment Anti-PD-(L)1s plus chemotherapies continue to evolve- Updates from 2023 congresses (Video MP4 Format)
GSK – The breakthrough era in endometrial cancer treatment Full discussion_Q&A (Video MP4 Format)
GSK – The breakthrough era in endometrial cancer treatment Surge in molecular-based targets brings new hope for EC treatment (Video MP4 Format)
GSK – The breakthrough era in endometrial cancer treatment Synergy- Is it more than a buzzword for IO plus PARPi or TKI- (Video MP4 Format)
GSK – The breakthrough era in endometrial cancer treatment Three ways EC management is changing (Video MP4 Format)
GSK – The Need for Better Patient Outcomes Locally Advanced dMMR_MSI-H Colon Cancer- New Approaches Under Investigation (Video MP4 Format)
GSK – The Need for Better Patient Outcomes Locally Advanced dMMR_MSI-H Rectal Cancer- New Approaches Under Investigation (Video MP4 Format)
GSK – The Need for Better Patient Outcomes Q&A – Panel Discussion (Video MP4 Format)
GSK – The Need for Better Patient Outcomes The Multidisciplinary Approach to Locally Advanced dMMR_MSI-H CRC- Reducing the Patient Burden (Video MP4 Format)
GSK – The Need for Better Patient Outcomes The Need for New Approaches in Locally Advanced dMMR_MSI-H CRC (Video MP4 Format)
Harnessing innate immunity to fight cancer Are Gamma Delta T cells the protagonists of cancer attack by the innate immune system (Video MP4 Format)
Harnessing innate immunity to fight cancer Are Gamma Delta T cells the protagonists of cancer attack by the innate immune system (PDF Format)
Harnessing innate immunity to fight cancer Cytokine cis-targeting to selectively activate tumor-specific immunity (Video MP4 Format)
Harnessing innate immunity to fight cancer Q&A and Discussion (Video MP4 Format)
Harnessing innate immunity to fight cancer The Type 2 immune axis in the marrow directs pro-tumorigenic myelopoiesis (Video MP4 Format)
Harnessing innate immunity to fight cancer The Type 2 immune axis in the marrow directs pro-tumorigenic myelopoiesis (PDF Format)
Healthcare in times of crises Healthcare in times of crises (Video MP4 Format)
Healthcare in times of crises Healthcare in times of crises (PDF Format)
Healthcare in times of crises Introduction by the Chair (Video MP4 Format)
Healthcare in times of crises Introduction by the Chair (PDF Format)
HER2 positive gastroesophageal cancer Conclusions and perspectives (Video MP4 Format)
HER2 positive gastroesophageal cancer Discussion (Video MP4 Format)
HER2 positive gastroesophageal cancer Discussion (PDF Format)
HER2 positive gastroesophageal cancer HER2 and beyond- What’s next (Video MP4 Format)
HER2 positive gastroesophageal cancer HER2 and beyond- What’s next (PDF Format)
HER2 positive gastroesophageal cancer Introduction and scientific background (Video MP4 Format)
HER2 positive gastroesophageal cancer Lessons from the biology of HER2 positive gastroesophageal cancer (Video MP4 Format)
HER2 positive gastroesophageal cancer Lessons from the biology of HER2 positive gastroesophageal cancer (PDF Format)
HER2 positive gastroesophageal cancer Novel therapies in HER2 in advanced gastroesophageal cancer (Video MP4 Format)
HER2 positive gastroesophageal cancer Novel therapies in HER2 in advanced gastroesophageal cancer (PDF Format)
HER2 positive gastroesophageal cancer Targeting HER2 in operable gastroesophageal cancer (Video MP4 Format)
HER2 positive gastroesophageal cancer Targeting HER2 in operable gastroesophageal cancer (PDF Format)
How do we best monitor patients during follow-up Discussion (Video MP4 Format)
How do we best monitor patients during follow-up Discussion (PDF Format)
How do we best monitor patients during follow-up Introduction (Video MP4 Format)
How do we best monitor patients during follow-up Introduction (PDF Format)
How do we best monitor patients during follow-up It is not just survival- Rehabilitation, quality of life and late toxicities (Video MP4 Format)
How do we best monitor patients during follow-up It is not just survival- Rehabilitation, quality of life and late toxicities (PDF Format)
How do we best monitor patients during follow-up Liquid biopsy may improve a tailored follow up (Video MP4 Format)
How do we best monitor patients during follow-up Liquid biopsy may improve a tailored follow up (PDF Format)
How do we best monitor patients during follow-up Minimalist or maximalist- From literature to real-world data (Video MP4 Format)
How do we best monitor patients during follow-up Minimalist or maximalist- From literature to real-world data (PDF Format)
How do we best monitor patients during follow-up Radiological imaging vs clinical examination- When less is more (Video MP4 Format)
How do we best monitor patients during follow-up Radiological imaging vs clinical examination- When less is more (PDF Format)
How do we best monitor patients during follow-up The patient’s perspective and expectations (Video MP4 Format)
How do we best monitor patients during follow-up The patient’s perspective and expectations (PDF Format)
How do we manage patients with complicated toxicity to immunotherapy Discussion led by Chair (Video MP4 Format)
How do we manage patients with complicated toxicity to immunotherapy Discussion led by Chair (PDF Format)
How do we manage patients with complicated toxicity to immunotherapy Presentation by Expert (Video MP4 Format)
How do we manage patients with complicated toxicity to immunotherapy Presentation by Expert (PDF Format)
How does digitalisation help personalised care throughout the patient journey Discussion (Video MP4 Format)
How does digitalisation help personalised care throughout the patient journey Discussion (PDF Format)
How does digitalisation help personalised care throughout the patient journey New solutions for cancer patients (Video MP4 Format)
How does digitalisation help personalised care throughout the patient journey New solutions for cancer patients (PDF Format)
How does digitalisation help personalised care throughout the patient journey New technologies in hospitals, improving patient experience (Video MP4 Format)
How does digitalisation help personalised care throughout the patient journey New technologies in hospitals, improving patient experience (PDF Format)
How does digitalisation help personalised care throughout the patient journey Patients at the centre of the new digital solutions- HealthDay and personalised care (Video MP4 Format)
How does digitalisation help personalised care throughout the patient journey Patients at the centre of the new digital solutions- HealthDay and personalised care (PDF Format)
How does digitalisation help personalised care throughout the patient journey Saving life trough tracking symptoms and early detection of cancer recurrence- The importance of collecting data in registries (Video MP4 Format)
How does digitalisation help personalised care throughout the patient journey Saving life trough tracking symptoms and early detection of cancer recurrence- The importance of collecting data in registries (PDF Format)
How does digitalisation help personalised care throughout the patient journey Virtual nursing services- Data for healthier patient lives (Video MP4 Format)
How does digitalisation help personalised care throughout the patient journey Virtual nursing services- Data for healthier patient lives (PDF Format)
How to improve access to medicines through patient engagement A gap analysis on access to modern medicines and treatments (Video MP4 Format)
How to improve access to medicines through patient engagement A gap analysis on access to modern medicines and treatments (PDF Format)
How to improve access to medicines through patient engagement Discussion (Video MP4 Format)
How to improve access to medicines through patient engagement Incorporating patient organizations’ expertise into the healthcare legislation (Video MP4 Format)
How to improve access to medicines through patient engagement Incorporating patient organizations’ expertise into the healthcare legislation (PDF Format)
How to improve access to medicines through patient engagement Leukaemia care and the collaboration with NICE (Video MP4 Format)
How to improve access to medicines through patient engagement Leukaemia care and the collaboration with NICE (PDF Format)
How to improve access to medicines through patient engagement Patient engagement and collaboration with national regulatory agencies (Video MP4 Format)
How to improve access to medicines through patient engagement Patient engagement and collaboration with national regulatory agencies (PDF Format)
How to improve access to medicines through patient engagement The improvement of the regulatory process through the consideration of patients (Video MP4 Format)
How to improve access to medicines through patient engagement The improvement of the regulatory process through the consideration of patients (PDF Format)
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for biliary cancer (Video MP4 Format)
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for biliary cancer (PDF Format)
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for liver cancer (Video MP4 Format)
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for liver cancer (PDF Format)
How to navigate the different treatment options for hepatobiliary cancers Personalised medicine and targeted agents for biliary tract cancer (Video MP4 Format)
How to navigate the different treatment options for hepatobiliary cancers Personalised medicine and targeted agents for biliary tract cancer (PDF Format)
How to navigate the different treatment options for hepatobiliary cancers Personalised treatment for HCC- Where are we now (Video MP4 Format)
How to navigate the different treatment options for hepatobiliary cancers Personalised treatment for HCC- Where are we now (PDF Format)
How to navigate the different treatment options for hepatobiliary cancers Q&A and Discussion (Video MP4 Format)
How to navigate the different treatment options for hepatobiliary cancers Q&A and Discussion (PDF Format)
Immunotherapy for head and neck cancer What, when and how long Conclusions and perspectives (Video MP4 Format)
Immunotherapy for head and neck cancer What, when and how long Conclusions and perspectives (PDF Format)
Immunotherapy for head and neck cancer What, when and how long Discussion (Video MP4 Format)
Immunotherapy for head and neck cancer What, when and how long Discussion (PDF Format)
Immunotherapy for head and neck cancer What, when and how long Incorporating immunotherapy into the approach to locally advanced HNSCC (Video MP4 Format)
Immunotherapy for head and neck cancer What, when and how long Incorporating immunotherapy into the approach to locally advanced HNSCC (PDF Format)
Immunotherapy for head and neck cancer What, when and how long Introduction and scientific background (Video MP4 Format)
Immunotherapy for head and neck cancer What, when and how long Introduction and scientific background (PDF Format)
Immunotherapy for head and neck cancer What, when and how long Novel combinations in the non-curative HNSCC setting (Video MP4 Format)
Immunotherapy for head and neck cancer What, when and how long Novel combinations in the non-curative HNSCC setting (PDF Format)
Immunotherapy for head and neck cancer What, when and how long Patient selection is crucial to improve immunotherapy effectiveness (Video MP4 Format)
Immunotherapy for head and neck cancer What, when and how long Patient selection is crucial to improve immunotherapy effectiveness (PDF Format)
Immunotherapy for head and neck cancer What, when and how long Perioperative immunotherapy for head and neck squamous cell carcinoma (HNSCC) (Video MP4 Format)
Immunotherapy for head and neck cancer What, when and how long Perioperative immunotherapy for head and neck squamous cell carcinoma (HNSCC) (PDF Format)
Immunotherapy in colorectal cancer Where do we stand and what do we expect Discussion led by Chair (Video MP4 Format)
Immunotherapy in colorectal cancer Where do we stand and what do we expect Discussion led by Chair (PDF Format)
Immunotherapy in colorectal cancer Where do we stand and what do we expect Presentation by Expert (Video MP4 Format)
Immunotherapy in colorectal cancer Where do we stand and what do we expect Presentation by Expert (PDF Format)
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Discussion led by Chair (Video MP4 Format)
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Discussion led by Chair (PDF Format)
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Presentation by Expert (Video MP4 Format)
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Presentation by Expert (PDF Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Discussion (Video MP4 Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Discussion (PDF Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Geriatric assessment It is primetime now (Video MP4 Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Geriatric assessment It is primetime now (PDF Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced breast cancer (Video MP4 Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced breast cancer (PDF Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced colorectal cancer (Video MP4 Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced colorectal cancer (PDF Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced lung cancer (Video MP4 Format)
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced lung cancer (PDF Format)
In collaboration with the IARC – Cancer prevention Discussion (Video MP4 Format)
In collaboration with the IARC – Cancer prevention Discussion (PDF Format)
In collaboration with the IARC – Cancer prevention IARC’s European Code Against Cancer- The EONS-ESMO campaign (Video MP4 Format)
In collaboration with the IARC – Cancer prevention IARC’s European Code Against Cancer- The EONS-ESMO campaign (PDF Format)
In collaboration with the IARC – Cancer prevention Introduction (Video MP4 Format)
In collaboration with the IARC – Cancer prevention Introduction (PDF Format)
In collaboration with the IARC – Cancer prevention Presentation of the IARC-ESMO survey results on the educational needs of medical oncologists on cancer (Video MP4 Format)
In collaboration with the IARC – Cancer prevention Presentation of the IARC-ESMO survey results on the educational needs of medical oncologists on cancer (PDF Format)
In collaboration with the IARC – Cancer prevention The IARC World Cancer Report Updates Learning Platform – Supported by ESMO (Video MP4 Format)
In collaboration with the IARC – Cancer prevention The IARC World Cancer Report Updates Learning Platform – Supported by ESMO (PDF Format)
In collaboration with the IARC – Cancer prevention The present and future of lung cancer screening What does the scientific evidence show (Video MP4 Format)
In collaboration with the IARC – Cancer prevention The present and future of lung cancer screening What does the scientific evidence show (PDF Format)
In collaboration with the IARC – Cancer prevention WHO’s cancer prevention policy resolutions, best buys, and framework convention on tobacco control (Video MP4 Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue in health care professionals Another term for burnout (Video MP4 Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue in health care professionals Another term for burnout (PDF Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue related to emerging targeted anticancer therapeutics (Video MP4 Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue related to emerging targeted anticancer therapeutics (PDF Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Panel discussion Q&A (Video MP4 Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Panel discussion Q&A (PDF Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Systemic anticancer therapy-related fatigue Causes and management (Video MP4 Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Systemic anticancer therapy-related fatigue Causes and management (PDF Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem The epidemiology, biology and aetiology of cancer-related fatigue (Video MP4 Format)
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem The epidemiology, biology and aetiology of cancer-related fatigue (PDF Format)
Integrating immunotherapy into the standard of care for cervical cancer Discussion (Video MP4 Format)
Integrating immunotherapy into the standard of care for cervical cancer In metastatic and recurrence (Video MP4 Format)
Integrating immunotherapy into the standard of care for cervical cancer In metastatic and recurrence (PDF Format)
Integrating immunotherapy into the standard of care for cervical cancer IO in combination with chemoradiation therapy in locally advanced cervical cancer (Video MP4 Format)
Integrating immunotherapy into the standard of care for cervical cancer IO in combination with chemoradiation therapy in locally advanced cervical cancer (PDF Format)
Integrating immunotherapy into the standard of care for cervical cancer Treatment after progression on immunotherapy (Video MP4 Format)
Integrating immunotherapy into the standard of care for cervical cancer Treatment after progression on immunotherapy (PDF Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Beyond medical oncology in the management of metastatic disease (Video MP4 Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Beyond medical oncology in the management of metastatic disease (PDF Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Discussion (Video MP4 Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Discussion (PDF Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for CNS metastatic disease (Video MP4 Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for CNS metastatic disease (PDF Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for non-CNS metastatic disease (Video MP4 Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for non-CNS metastatic disease (PDF Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with CNS met condition (Video MP4 Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with CNS met condition (PDF Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with extra cranial met condition (Video MP4 Format)
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with extra cranial met condition (PDF Format)
Intensification vs descalation of therapy in H&N cancer When and for whom De-escalation in radiation and systemic therapy (Video MP4 Format)
Intensification vs descalation of therapy in H&N cancer When and for whom De-escalation in radiation and systemic therapy (PDF Format)
Intensification vs descalation of therapy in H&N cancer When and for whom Novel strategies to de-escalate surgery (Video MP4 Format)
Intensification vs descalation of therapy in H&N cancer When and for whom Novel strategies to de-escalate surgery (PDF Format)
Intensification vs descalation of therapy in H&N cancer When and for whom Q&A and Discussion (Video MP4 Format)
Intensification vs descalation of therapy in H&N cancer When and for whom Q&A and Discussion (PDF Format)
Intensification vs descalation of therapy in H&N cancer When and for whom Which patients need more intensive treatment (Video MP4 Format)
Intensification vs descalation of therapy in H&N cancer When and for whom Which patients need more intensive treatment (PDF Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Presentation of case condition (Video MP4 Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Presentation of case condition (PDF Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Q&A and Discussion (Video MP4 Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Q&A and Discussion (PDF Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of locoregional and ablative therapies (Video MP4 Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of locoregional and ablative therapies (PDF Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of surgery in advanced disease (Video MP4 Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of surgery in advanced disease (PDF Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of systemic therapies in the control of hormone-release (Video MP4 Format)
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of systemic therapies in the control of hormone-release (PDF Format)
Ipsen aRCC and mCRPC is your decision-making up-to-date Closing Remarks (Video MP4 Format)
Ipsen aRCC and mCRPC is your decision-making up-to-date Direction of travel in mCRPC Description- A presentation reflecting on the similar rapid changes that are occurring in mCRPC and changes anticipated in the near-term, and considering th (Video MP4 Format)
Ipsen aRCC and mCRPC is your decision-making up-to-date Keeping pace in aRCC Description- A presentation highlighting the rapid advances in treatment landscape as well as biological understanding of aRCC, and what this means for patients in (Video MP4 Format)
Ipsen aRCC and mCRPC is your decision-making up-to-date Panel Discussion (Video MP4 Format)
Ipsen aRCC and mCRPC is your decision-making up-to-date Putting theory into practice Description- A simulated multi-disciplinary tumour board considering the first- and second-line treatment choices for a patient with aRCC (Video MP4 Format)
Ipsen aRCC and mCRPC is your decision-making up-to-date Spoilt for choice in 1L aRCC- Or not Really- Description- A presentation discussing the clinical endpoints that are considered when selecting first-line treatment for patients with aRCC (Video MP4 Format)
Ipsen aRCC and mCRPC is your decision-making up-to-date Welcome & introduction (Video MP4 Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types How to personalise neoadjuvant immunotherapy (Video MP4 Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types How to personalise neoadjuvant immunotherapy (PDF Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Is chemotherapy plus immunotherapy equal to immunotherapy alone at the neoadjuvant stage (Video MP4 Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Is chemotherapy plus immunotherapy equal to immunotherapy alone at the neoadjuvant stage (PDF Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Novel neoadjuvant combination immunotherapies (Video MP4 Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Novel neoadjuvant combination immunotherapies (PDF Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Q&A and Discussion (Video MP4 Format)
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Q&A and Discussion (PDF Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A radiation oncologist’s perspective (Video MP4 Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A radiation oncologist’s perspective (PDF Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A surgeon’s perspective (Video MP4 Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A surgeon’s perspective (PDF Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Characteristics and treatment outcomes of screening-detected early NSCLC (Video MP4 Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Characteristics and treatment outcomes of screening-detected early NSCLC (PDF Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Discussion (Video MP4 Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Discussion (PDF Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Opportunities for immunotherapy in stage I NSCLC (Video MP4 Format)
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Opportunities for immunotherapy in stage I NSCLC (PDF Format)
Is there still a place for anthracyclines in early breast cancer Discussion led by Chair (Video MP4 Format)
Is there still a place for anthracyclines in early breast cancer Discussion led by Chair (PDF Format)
Is there still a place for anthracyclines in early breast cancer Presentation by Expert (Video MP4 Format)
Is there still a place for anthracyclines in early breast cancer Presentation by Expert (PDF Format)
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Closing remarks (Video MP4 Format)
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Germ line testing and genomic profiling – isn’t it time for personalised prostate cancer care- (Video MP4 Format)
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care How can we balance efficacy and QoL in mHSPC treatment- Why it’s time to tailor treatments (Video MP4 Format)
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Interactive Q&A session (Video MP4 Format)
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Opening remarks & introduction (Video MP4 Format)
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Revolutionising urothelial carcinoma care- Discovering the value of targeted therapy (Video MP4 Format)
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Current and future directions for EGFR exon 20 insertion mutations in NSCLC (Video MP4 Format)
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Expanding our horizons- Novel frontline approaches in EGFR-mutant NSCLC (Video MP4 Format)
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Key learnings_closing remarks (Video MP4 Format)
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Strategies for overcoming EGFR resistance in NSCLC patient management (Video MP4 Format)
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Welcome and introductions (Video MP4 Format)
Liquid biopsies development and application Where do we stand Detection of HPV circulating tumour DNA (Video MP4 Format)
Liquid biopsies development and application Where do we stand Detection of HPV circulating tumour DNA (PDF Format)
Liquid biopsies development and application Where do we stand Genome-wide cell-free DNA fragmentation in cancer (Video MP4 Format)
Liquid biopsies development and application Where do we stand Genome-wide cell-free DNA fragmentation in cancer (PDF Format)
Liquid biopsies development and application Where do we stand Incorporating liquid biopsies into clinical trials (Video MP4 Format)
Liquid biopsies development and application Where do we stand Incorporating liquid biopsies into clinical trials (PDF Format)
Liquid biopsies development and application Where do we stand Q&A and Discussion (Video MP4 Format)
Liquid biopsies development and application Where do we stand Q&A and Discussion (PDF Format)
Liquid biopsies development and application Where do we stand Standardisation of liquid biopsy approaches (Video MP4 Format)
Liquid biopsies development and application Where do we stand Standardisation of liquid biopsy approaches (PDF Format)
Living with and after cancer Behavioural changes in daily life- A cross-cutting approach for daily wellbeing (Video MP4 Format)
Living with and after cancer Behavioural changes in daily life- A cross-cutting approach for daily wellbeing (PDF Format)
Living with and after cancer Conclusion (Video MP4 Format)
Living with and after cancer Conclusion (PDF Format)
Living with and after cancer Discussion (Video MP4 Format)
Living with and after cancer Discussion (PDF Format)
Living with and after cancer Palliative and supportive care (Video MP4 Format)
Living with and after cancer Palliative and supportive care (PDF Format)
Living with and after cancer Quality of life and survivorship (Video MP4 Format)
Living with and after cancer Quality of life and survivorship (PDF Format)
Living with and after cancer Reducing inequalities in Europe through robust national cancer control plans that include palliative care (Video MP4 Format)
Living with and after cancer Reducing inequalities in Europe through robust national cancer control plans that include palliative care (PDF Format)
Living with and after cancer Resilience is key after diagnosis, during treatment, and after treatment (Video MP4 Format)
Living with and after cancer Resilience is key after diagnosis, during treatment, and after treatment (PDF Format)
Long term survivors in the era of immunotherapy of cancer Cognitive defects in long term IO (Video MP4 Format)
Long term survivors in the era of immunotherapy of cancer Cognitive defects in long term IO (PDF Format)
Long term survivors in the era of immunotherapy of cancer Discussion (Video MP4 Format)
Long term survivors in the era of immunotherapy of cancer Discussion (PDF Format)
Long term survivors in the era of immunotherapy of cancer Ideal duration of IT- How to define it and what are the implications (Video MP4 Format)
Long term survivors in the era of immunotherapy of cancer Ideal duration of IT- How to define it and what are the implications (PDF Format)
Long term survivors in the era of immunotherapy of cancer Long-term toxicity of immunotherapeutics (Video MP4 Format)
Long term survivors in the era of immunotherapy of cancer Long-term toxicity of immunotherapeutics (PDF Format)
Long term survivors in the era of immunotherapy of cancer Quality of life in IO-treated long-term survivors (Video MP4 Format)
Long term survivors in the era of immunotherapy of cancer Quality of life in IO-treated long-term survivors (PDF Format)
Looking ahead in SCLC From biology to clinical practice Discussion led by Chair (Video MP4 Format)
Looking ahead in SCLC From biology to clinical practice Discussion led by Chair (PDF Format)
Looking ahead in SCLC From biology to clinical practice Presentation by Expert (Video MP4 Format)
Looking ahead in SCLC From biology to clinical practice Presentation by Expert (PDF Format)
Making essential cancer drugs affordable Governmental policies to control cancer medicine prices (Video MP4 Format)
Making essential cancer drugs affordable Governmental policies to control cancer medicine prices (PDF Format)
Making essential cancer drugs affordable India’s approach to advance access to cancer medicines (Video MP4 Format)
Making essential cancer drugs affordable India’s approach to advance access to cancer medicines (PDF Format)
Making essential cancer drugs affordable Insights in essential medicine availability and accessibility from ESMO antineoplastic medicines study 2.0 (Video MP4 Format)
Making essential cancer drugs affordable Insights in essential medicine availability and accessibility from ESMO antineoplastic medicines study 2.0 (PDF Format)
Making essential cancer drugs affordable Policy and intellectual property regulatory instruments as tools to enhance access to expensive essential cancer medicines (Video MP4 Format)
Making essential cancer drugs affordable Policy and intellectual property regulatory instruments as tools to enhance access to expensive essential cancer medicines (PDF Format)
Making essential cancer drugs affordable Q&A and Discussion (Video MP4 Format)
Making essential cancer drugs affordable Q&A and Discussion (PDF Format)
Management of (very) high-risk localised PCA Delineating staging pelvic LND before RT and positioning primary prostatectomy (Video MP4 Format)
Management of (very) high-risk localised PCA Delineating staging pelvic LND before RT and positioning primary prostatectomy (PDF Format)
Management of (very) high-risk localised PCA Dose intensification and field expansion of EBRT (Video MP4 Format)
Management of (very) high-risk localised PCA Dose intensification and field expansion of EBRT (PDF Format)
Management of (very) high-risk localised PCA How much systemic treatment is needed and how long (Video MP4 Format)
Management of (very) high-risk localised PCA How much systemic treatment is needed and how long (PDF Format)
Management of (very) high-risk localised PCA Presentation of case condition (Video MP4 Format)
Management of (very) high-risk localised PCA Presentation of case condition (PDF Format)
Management of (very) high-risk localised PCA Q&A and Discussion (Video MP4 Format)
Management of (very) high-risk localised PCA Q&A and Discussion (PDF Format)
Management of (very) high-risk localised PCA Usefulness and limitations of PSMA imaging PET in high-risk localised disease (Video MP4 Format)
Management of (very) high-risk localised PCA Usefulness and limitations of PSMA imaging PET in high-risk localised disease (PDF Format)
Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC) Discussion led by Chair (Video MP4 Format)
Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC) Presentation by Expert (Video MP4 Format)
Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC) Presentation by Expert (PDF Format)
Management of novel treatments toxicities Discussion and Q&A (Video MP4 Format)
Management of novel treatments toxicities Discussion and Q&A (PDF Format)
Management of novel treatments toxicities Management of antibody-drug conjugates toxicities (Video MP4 Format)
Management of novel treatments toxicities Management of antibody-drug conjugates toxicities (PDF Format)
Management of novel treatments toxicities Toxicities of novel therapies Why is that important (Video MP4 Format)
Management of novel treatments toxicities Toxicities of novel therapies Why is that important (PDF Format)
Management of novel treatments toxicities Toxicities of TILs, CAR-Ts and bispecific antibodies (Video MP4 Format)
Management of novel treatments toxicities Toxicities of TILs, CAR-Ts and bispecific antibodies (PDF Format)
Management of novel treatments toxicities Toxicity of IO + targeted agents (Video MP4 Format)
Management of novel treatments toxicities Toxicity of IO + targeted agents (PDF Format)
Management of oligometastatic disease in NSCLC Introduction and definition of oligometastatic disease(s) Case presentation (Video MP4 Format)
Management of oligometastatic disease in NSCLC Introduction and definition of oligometastatic disease(s) Case presentation (PDF Format)
Management of oligometastatic disease in NSCLC Q&A and Discussion (Video MP4 Format)
Management of oligometastatic disease in NSCLC Q&A and Discussion (PDF Format)
Management of oligometastatic disease in NSCLC The role of radiation therapy (Video MP4 Format)
Management of oligometastatic disease in NSCLC The role of radiation therapy (PDF Format)
Management of oligometastatic disease in NSCLC The role of surgery (Video MP4 Format)
Management of oligometastatic disease in NSCLC The role of surgery (PDF Format)
Management of oligometastatic disease in NSCLC The role of systemic therapy in patients with or without molecular alterations (Video MP4 Format)
Management of oligometastatic disease in NSCLC The role of systemic therapy in patients with or without molecular alterations (PDF Format)
Management of retroperitoneal sarcoma A medical oncologist’s perspective (Video MP4 Format)
Management of retroperitoneal sarcoma A medical oncologist’s perspective (PDF Format)
Management of retroperitoneal sarcoma A pathologist’s perspective (Video MP4 Format)
Management of retroperitoneal sarcoma A pathologist’s perspective (PDF Format)
Management of retroperitoneal sarcoma A radiation oncologist’s perspective (Video MP4 Format)
Management of retroperitoneal sarcoma A radiation oncologist’s perspective (PDF Format)
Management of retroperitoneal sarcoma A surgeon’s perspective (Video MP4 Format)
Management of retroperitoneal sarcoma A surgeon’s perspective (PDF Format)
Management of retroperitoneal sarcoma Discussion (Video MP4 Format)
Management of retroperitoneal sarcoma Discussion (PDF Format)
Management of retroperitoneal sarcoma Presentation of case condition (Video MP4 Format)
Management of retroperitoneal sarcoma Presentation of case condition (PDF Format)
Managing disease progression in oncogene-driven lung cancer Detection From technology to clinical practice (Video MP4 Format)
Managing disease progression in oncogene-driven lung cancer Detection From technology to clinical practice (PDF Format)
Managing disease progression in oncogene-driven lung cancer Discussion (Video MP4 Format)
Managing disease progression in oncogene-driven lung cancer Discussion (PDF Format)
Managing disease progression in oncogene-driven lung cancer Managing progression after EGFR TKIs in EGFR-mutant lung cancer (Video MP4 Format)
Managing disease progression in oncogene-driven lung cancer Managing progression after EGFR TKIs in EGFR-mutant lung cancer (PDF Format)
Managing disease progression in oncogene-driven lung cancer Managing progression after TKIs in oncogenic fusion-driven lung cancer (Video MP4 Format)
Managing disease progression in oncogene-driven lung cancer Managing progression after TKIs in oncogenic fusion-driven lung cancer (PDF Format)
Managing disease progression in oncogene-driven lung cancer Mechanisms of resistance (Video MP4 Format)
Managing disease progression in oncogene-driven lung cancer Mechanisms of resistance (PDF Format)
Managing stage III NSCLC in the era of IO IO after or with chemoradiotherapy For how long (Video MP4 Format)
Managing stage III NSCLC in the era of IO IO after or with chemoradiotherapy For how long (PDF Format)
Managing stage III NSCLC in the era of IO IO and chemotherapy before or after surgery (Video MP4 Format)
Managing stage III NSCLC in the era of IO IO and chemotherapy before or after surgery (PDF Format)
Managing stage III NSCLC in the era of IO Presentation of case condition (Video MP4 Format)
Managing stage III NSCLC in the era of IO Presentation of case condition (PDF Format)
Managing stage III NSCLC in the era of IO Q&A and Discussion (Video MP4 Format)
Managing stage III NSCLC in the era of IO Q&A and Discussion (PDF Format)
Managing stage III NSCLC in the era of IO Who should and shouldn’t get surgery (Video MP4 Format)
Managing stage III NSCLC in the era of IO Who should and shouldn’t get surgery (PDF Format)
Mini oral session – Basic science & translational research A randomized phase III trial of site-specific therapy guided (Video MP4 Format)
Mini oral session – Basic science & translational research A randomized phase III trial of site-specific therapy guided (PDF Format)
Mini oral session – Basic science & translational research BRCA-DIRECT- A randomised UK study evaluating a digital pathway (Video MP4 Format)
Mini oral session – Basic science & translational research BRCA-DIRECT- A randomised UK study evaluating a digital pathway (PDF Format)
Mini oral session – Basic science & translational research CDC7 inhibition constrains lineage plasticity (Video MP4 Format)
Mini oral session – Basic science & translational research CDC7 inhibition constrains lineage plasticity (PDF Format)
Mini oral session – Basic science & translational research Comparison of clinical and radiological features-based and radiomics features-based (Video MP4 Format)
Mini oral session – Basic science & translational research Comparison of clinical and radiological features-based and radiomics features-based (PDF Format)
Mini oral session – Basic science & translational research Computer-aided HCC lesion detection based on deep learning and CT images (Video MP4 Format)
Mini oral session – Basic science & translational research Computer-aided HCC lesion detection based on deep learning and CT images (PDF Format)
Mini oral session – Basic science & translational research CUP-ONE trial A prospective double-blind validation (Video MP4 Format)
Mini oral session – Basic science & translational research CUP-ONE trial A prospective double-blind validation (PDF Format)
Mini oral session – Basic science & translational research Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma (Video MP4 Format)
Mini oral session – Basic science & translational research Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma (PDF Format)
Mini oral session – Basic science & translational research Invited Discussant 1209MO and 1210MO (Video MP4 Format)
Mini oral session – Basic science & translational research Invited Discussant 1209MO and 1210MO (PDF Format)
Mini oral session – Basic science & translational research Invited Discussant 132MO, LBA100, 1208MO and LBA101 (Video MP4 Format)
Mini oral session – Basic science & translational research Invited Discussant 132MO, LBA100, 1208MO and LBA101 (PDF Format)
Mini oral session – Basic science & translational research Invited Discussant 2233MO and 133MO (Video MP4 Format)
Mini oral session – Basic science & translational research Invited Discussant 2233MO and 133MO (PDF Format)
Mini oral session – Basic science & translational research olecular profiling of 991 prospectively recruited rare cancers patients in EUROPE (Video MP4 Format)
Mini oral session – Basic science & translational research olecular profiling of 991 prospectively recruited rare cancers patients in EUROPE (PDF Format)
Mini oral session – Breast cancer, early stage A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine (Video MP4 Format)
Mini oral session – Breast cancer, early stage A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine (PDF Format)
Mini oral session – Breast cancer, early stage Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) (Video MP4 Format)
Mini oral session – Breast cancer, early stage Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) (PDF Format)
Mini oral session – Breast cancer, early stage Connected device and therapeutic patient education to promote physical (Video MP4 Format)
Mini oral session – Breast cancer, early stage Connected device and therapeutic patient education to promote physical (PDF Format)
Mini oral session – Breast cancer, early stage Impact of body mass index and its change on survival outcomes in patients with early breast cancer (Video MP4 Format)
Mini oral session – Breast cancer, early stage Impact of body mass index and its change on survival outcomes in patients with early breast cancer (PDF Format)
Mini oral session – Breast cancer, early stage Invasive disease-free survival (iDFS) across key subgroups from the phase III (Video MP4 Format)
Mini oral session – Breast cancer, early stage Invasive disease-free survival (iDFS) across key subgroups from the phase III (PDF Format)
Mini oral session – Breast cancer, early stage Invited Discussant 238MO, LBA22 and 239MO (Video MP4 Format)
Mini oral session – Breast cancer, early stage Invited Discussant 238MO, LBA22 and 239MO (PDF Format)
Mini oral session – Breast cancer, early stage Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24 (Video MP4 Format)
Mini oral session – Breast cancer, early stage Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24 (PDF Format)
Mini oral session – Breast cancer, early stage Invited Discussant 243MO and 244MO (Video MP4 Format)
Mini oral session – Breast cancer, early stage Invited Discussant 243MO and 244MO (PDF Format)
Mini oral session – Breast cancer, early stage Long-term residential and workplace exposure to air pollution and breast cancer risk (Video MP4 Format)
Mini oral session – Breast cancer, early stage Long-term residential and workplace exposure to air pollution and breast cancer risk (PDF Format)
Mini oral session – Breast cancer, early stage Multiparametric prognostic score in early HR+ (Video MP4 Format)
Mini oral session – Breast cancer, early stage Multiparametric prognostic score in early HR+ (PDF Format)
Mini oral session – Breast cancer, early stage Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer (Video MP4 Format)
Mini oral session – Breast cancer, early stage Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer (PDF Format)
Mini oral session – Breast cancer, early stage Patient characteristics and real-world outcomes in HER2 negative (Video MP4 Format)
Mini oral session – Breast cancer, early stage Patient characteristics and real-world outcomes in HER2 negative (PDF Format)
Mini oral session – Breast cancer, early stage Prognostic and predictive impact of estrogen progesterone receptor (ER PR) (Video MP4 Format)
Mini oral session – Breast cancer, early stage Prognostic and predictive impact of estrogen progesterone receptor (ER PR) (PDF Format)
Mini oral session – Breast cancer, metastatic A multicenter, open-label, dose escalation and expansion study of DP303c (Video MP4 Format)
Mini oral session – Breast cancer, metastatic A multicenter, open-label, dose escalation and expansion study of DP303c (PDF Format)
Mini oral session – Breast cancer, metastatic Datopotamab deruxtecan (Dato-DXd) durvalumab (D) as first-line (1L) (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Datopotamab deruxtecan (Dato-DXd) durvalumab (D) as first-line (1L) (PDF Format)
Mini oral session – Breast cancer, metastatic Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (PDF Format)
Mini oral session – Breast cancer, metastatic First results of the SOLTI-1903 HOPE’s patient-centric molecular screening program in advanced breast cancer (Video MP4 Format)
Mini oral session – Breast cancer, metastatic First results of the SOLTI-1903 HOPE’s patient-centric molecular screening program in advanced breast cancer (PDF Format)
Mini oral session – Breast cancer, metastatic Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC) (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC) (PDF Format)
Mini oral session – Breast cancer, metastatic Invited Discussant 379MO and 380MO (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Invited Discussant 379MO and 380MO (PDF Format)
Mini oral session – Breast cancer, metastatic Invited Discussant 382MO, 383MO and 384MO (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Invited Discussant 382MO, 383MO and 384MO (PDF Format)
Mini oral session – Breast cancer, metastatic Invited Discussant 385MO, 386MO and 387MO (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Invited Discussant 385MO, 386MO and 387MO (PDF Format)
Mini oral session – Breast cancer, metastatic SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+) (Video MP4 Format)
Mini oral session – Breast cancer, metastatic SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+) (PDF Format)
Mini oral session – Breast cancer, metastatic Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer (PDF Format)
Mini oral session – Breast cancer, metastatic Updated results from the phase I II study of OP-1250, an oral complete estrogen receptor (Video MP4 Format)
Mini oral session – Breast cancer, metastatic Updated results from the phase I II study of OP-1250, an oral complete estrogen receptor (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive 554MO – Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive 554MO – Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive 555MO – Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS BRAF (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive 555MO – Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS BRAF (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive 556MO – A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive 556MO – A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive 557MO – Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive 557MO – Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive 558MO – Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC) (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive 558MO – Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC) (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive 559MO – Rechallenge with EGFR inhibitors in ctDNA RAS BRAF wild type refractory metastatic colorectal cancer (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive 559MO – Rechallenge with EGFR inhibitors in ctDNA RAS BRAF wild type refractory metastatic colorectal cancer (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive 560MO – Maintenance with 5FU LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive 560MO – Maintenance with 5FU LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant 558MO, 559MO and 560MO (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant 558MO, 559MO and 560MO (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA30, 554MO and 555MO (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA30, 554MO and 555MO (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA31, 556MO, LBA32 and 557MO (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA31, 556MO, LBA32 and 557MO (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive LBA30 – Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive LBA30 – Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive LBA31 – Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive LBA31 – Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers (PDF Format)
Mini oral session – Gastrointestinal tumours, lower digestive LBA32 – Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H) mismatch repair-deficient (dMMR) (Video MP4 Format)
Mini oral session – Gastrointestinal tumours, lower digestive LBA32 – Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H) mismatch repair-deficient (dMMR) (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate 1883MO – MEDI5752 (volrustomig), a novel PD-1 CTLA-4 bispecific antibody, in the first-line (1L) (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate 1883MO – MEDI5752 (volrustomig), a novel PD-1 CTLA-4 bispecific antibody, in the first-line (1L) (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate 1884MO – Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate 1884MO – Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate 2361MO – Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate 2361MO – Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate 2362MO – Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate 2362MO – Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate 2363MO – A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate 2363MO – A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate 2364MO – Durvalumab (D) +- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate 2364MO – Durvalumab (D) +- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate 2365MO – Study EV-103 cohort L Perioperative treatment w enfortumab vedotin (EV) monotherapy (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate 2365MO – Study EV-103 cohort L Perioperative treatment w enfortumab vedotin (EV) monotherapy (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 1883MO and 1884MO (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 1883MO and 1884MO (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2361MO and 2362MO (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2361MO and 2362MO (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2363MO, 2364MO and 2365MO (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2363MO, 2364MO and 2365MO (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant LBA104 and LBA105 (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant LBA104 and LBA105 (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate LBA104 – First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate LBA104 – First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system (PDF Format)
Mini oral session – Genitourinary tumours, non-prostate LBA105 – Results from SunRISe-1 in patients (Pts) with bacillus Calmette-Gu‚rin (BCG)-unresponsive high-risk (Video MP4 Format)
Mini oral session – Genitourinary tumours, non-prostate LBA105 – Results from SunRISe-1 in patients (Pts) with bacillus Calmette-Gu‚rin (BCG)-unresponsive high-risk (PDF Format)
Mini oral session – Genitourinary tumours, prostate 1766MO – Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate 1766MO – Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (PDF Format)
Mini oral session – Genitourinary tumours, prostate 1767MO – External validation of a digital pathology-based multimodal artificial intelligence (MMAI) (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate 1767MO – External validation of a digital pathology-based multimodal artificial intelligence (MMAI) (PDF Format)
Mini oral session – Genitourinary tumours, prostate 1768MO – Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate 1768MO – Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic (PDF Format)
Mini oral session – Genitourinary tumours, prostate 1771MO – Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate 1771MO – Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration (PDF Format)
Mini oral session – Genitourinary tumours, prostate 1772MO – Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate 1772MO – Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) (PDF Format)
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1766MO, 1767MO and 1768MO (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1766MO, 1767MO and 1768MO (PDF Format)
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1771MO, 1772MO, LBA85 and LBA86 (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1771MO, 1772MO, LBA85 and LBA86 (PDF Format)
Mini oral session – Genitourinary tumours, prostate LBA85 – Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate LBA85 – Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (PDF Format)
Mini oral session – Genitourinary tumours, prostate LBA86 – Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration (Video MP4 Format)
Mini oral session – Genitourinary tumours, prostate LBA86 – Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration (PDF Format)
Mini oral session – Gynaecological cancers 740MO – Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pArEC) (Video MP4 Format)
Mini oral session – Gynaecological cancers 740MO – Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pArEC) (PDF Format)
Mini oral session – Gynaecological cancers 741MO – Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRà) antibody drug conjugate (Video MP4 Format)
Mini oral session – Gynaecological cancers 741MO – Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRà) antibody drug conjugate (PDF Format)
Mini oral session – Gynaecological cancers 742MO – Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer (Video MP4 Format)
Mini oral session – Gynaecological cancers 742MO – Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer (PDF Format)
Mini oral session – Gynaecological cancers 743MO – Efficacy and safety of QL1706 plus paclitaxel and cisplatin carboplatin +- bevacizumab (Bev) (Video MP4 Format)
Mini oral session – Gynaecological cancers 743MO – Efficacy and safety of QL1706 plus paclitaxel and cisplatin carboplatin +- bevacizumab (Bev) (PDF Format)
Mini oral session – Gynaecological cancers 744MO – AdvanTIG-202- Phase II randomized, multicenter, open-label study of tislelizumab (TIS) (Video MP4 Format)
Mini oral session – Gynaecological cancers 744MO – AdvanTIG-202- Phase II randomized, multicenter, open-label study of tislelizumab (TIS) (PDF Format)
Mini oral session – Gynaecological cancers 745MO – Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC) (Video MP4 Format)
Mini oral session – Gynaecological cancers 745MO – Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC) (PDF Format)
Mini oral session – Gynaecological cancers 746MO – Randomized phase II trial of durvalumab in combination with olaparib and cediranib (Video MP4 Format)
Mini oral session – Gynaecological cancers 746MO – Randomized phase II trial of durvalumab in combination with olaparib and cediranib (PDF Format)
Mini oral session – Gynaecological cancers 747MO – First results from the ENGOT-GYN2 GOG-3051 BOUQUET phase II biomarker-directed platform study (Video MP4 Format)
Mini oral session – Gynaecological cancers 747MO – First results from the ENGOT-GYN2 GOG-3051 BOUQUET phase II biomarker-directed platform study (PDF Format)
Mini oral session – Gynaecological cancers Invited Discussant 743MO, 744MO and LBA44 (Video MP4 Format)
Mini oral session – Gynaecological cancers Invited Discussant 743MO, 744MO and LBA44 (PDF Format)
Mini oral session – Gynaecological cancers Invited Discussant 745MO and 747MO (Video MP4 Format)
Mini oral session – Gynaecological cancers Invited Discussant 745MO and 747MO (PDF Format)
Mini oral session – Gynaecological cancers Invited Discussant LBA43, 740MO, 742MO and 741MO (Video MP4 Format)
Mini oral session – Gynaecological cancers Invited Discussant LBA43, 740MO, 742MO and 741MO (PDF Format)
Mini oral session – Gynaecological cancers Invited Discussant LBA45 and 746MO (Video MP4 Format)
Mini oral session – Gynaecological cancers Invited Discussant LBA45 and 746MO (PDF Format)
Mini oral session – Gynaecological cancers LBA43 – Updated response data and analysis of progression free survival by mechanism of mismatch (Video MP4 Format)
Mini oral session – Gynaecological cancers LBA43 – Updated response data and analysis of progression free survival by mechanism of mismatch (PDF Format)
Mini oral session – Gynaecological cancers LBA44 – Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice (Video MP4 Format)
Mini oral session – Gynaecological cancers LBA44 – Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice (PDF Format)
Mini oral session – Gynaecological cancers LBA45 – Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib (Video MP4 Format)
Mini oral session – Gynaecological cancers LBA45 – Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib (PDF Format)
Mini oral session – Head and neck cancer 855MO – Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (Video MP4 Format)
Mini oral session – Head and neck cancer 855MO – Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (PDF Format)
Mini oral session – Head and neck cancer 856MO – A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) (Video MP4 Format)
Mini oral session – Head and neck cancer 856MO – A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) (PDF Format)
Mini oral session – Head and neck cancer 859MO – Sacituzumab govitecan (SG) in patients (pts) with relapsed refractory (R R) advanced head and neck (Video MP4 Format)
Mini oral session – Head and neck cancer 859MO – Sacituzumab govitecan (SG) in patients (pts) with relapsed refractory (R R) advanced head and neck (PDF Format)
Mini oral session – Head and neck cancer 860MO – MRG003- A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent metastatic nasopharyngeal carcinoma (Video MP4 Format)
Mini oral session – Head and neck cancer 860MO – MRG003- A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent metastatic nasopharyngeal carcinoma (PDF Format)
Mini oral session – Head and neck cancer Invited Discussant 855MO, 856MO and LBA46 (Video MP4 Format)
Mini oral session – Head and neck cancer Invited Discussant 855MO, 856MO and LBA46 (PDF Format)
Mini oral session – Head and neck cancer Invited Discussant 859MO, 860MO and LBA47 (Video MP4 Format)
Mini oral session – Head and neck cancer Invited Discussant 859MO, 860MO and LBA47 (PDF Format)
Mini oral session – Head and neck cancer LBA46 – SAKK 11 16, a phase IIa trial evaluating overall survival (OS) for recurrent metastatic Head & neck (Video MP4 Format)
Mini oral session – Head and neck cancer LBA46 – SAKK 11 16, a phase IIa trial evaluating overall survival (OS) for recurrent metastatic Head & neck (PDF Format)
Mini oral session – Head and neck cancer LBA47 – A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study) (Video MP4 Format)
Mini oral session – Head and neck cancer LBA47 – A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study) (PDF Format)
Mini oral session – Investigational immunotherapy 1020MO – AdvanTIG-203- Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (Video MP4 Format)
Mini oral session – Investigational immunotherapy 1020MO – AdvanTIG-203- Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (PDF Format)
Mini oral session – Investigational immunotherapy 1021MO – Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent advanced solid tumors (Video MP4 Format)
Mini oral session – Investigational immunotherapy 1021MO – Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent advanced solid tumors (PDF Format)
Mini oral session – Investigational immunotherapy 1022MO – Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy (Video MP4 Format)
Mini oral session – Investigational immunotherapy 1022MO – Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy (PDF Format)
Mini oral session – Investigational immunotherapy 1023MO – Decoding immunotherapy resistance A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes (Video MP4 Format)
Mini oral session – Investigational immunotherapy 1023MO – Decoding immunotherapy resistance A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes (PDF Format)
Mini oral session – Investigational immunotherapy 1024MO – Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate (Video MP4 Format)
Mini oral session – Investigational immunotherapy 1024MO – Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate (PDF Format)
Mini oral session – Investigational immunotherapy 1025MO – Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor (Video MP4 Format)
Mini oral session – Investigational immunotherapy 1025MO – Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor (PDF Format)
Mini oral session – Investigational immunotherapy 1026MO – A phase Ib II study of SHR-1701 (a bifunctional anti-PD-L1 TGF-áRII agent) in combination (Video MP4 Format)
Mini oral session – Investigational immunotherapy 1026MO – A phase Ib II study of SHR-1701 (a bifunctional anti-PD-L1 TGF-áRII agent) in combination (PDF Format)
Mini oral session – Investigational immunotherapy Invited Discussant 1020MO and 1021MO (Video MP4 Format)
Mini oral session – Investigational immunotherapy Invited Discussant 1020MO and 1021MO (PDF Format)
Mini oral session – Investigational immunotherapy Invited Discussant 1022MO, 1023MO and 1024MO (Video MP4 Format)
Mini oral session – Investigational immunotherapy Invited Discussant 1022MO, 1023MO and 1024MO (PDF Format)
Mini oral session – Investigational immunotherapy Invited Discussant 1025MO and 1026MO (Video MP4 Format)
Mini oral session – Investigational immunotherapy Invited Discussant 1025MO and 1026MO (PDF Format)
Mini oral session – Melanoma and other skin tumours 1083MO – Brain metastases and survival evaluation in the SECOMBIT trial (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours 1083MO – Brain metastases and survival evaluation in the SECOMBIT trial (PDF Format)
Mini oral session – Melanoma and other skin tumours 1084MO – Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours 1084MO – Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases (PDF Format)
Mini oral session – Melanoma and other skin tumours 1086MO – Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours 1086MO – Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal (PDF Format)
Mini oral session – Melanoma and other skin tumours 1087MO – A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours 1087MO – A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab (PDF Format)
Mini oral session – Melanoma and other skin tumours 1088MO – A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC) One-year follow-up (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours 1088MO – A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC) One-year follow-up (PDF Format)
Mini oral session – Melanoma and other skin tumours Invited Discussant 1083MO and 1084MO (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours Invited Discussant 1083MO and 1084MO (PDF Format)
Mini oral session – Melanoma and other skin tumours Invited Discussant 1087MO, 1088MO and LBA52 (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours Invited Discussant 1087MO, 1088MO and LBA52 (PDF Format)
Mini oral session – Melanoma and other skin tumours Invited Discussant LBA50, 1086MO and LBA51 (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours Invited Discussant LBA50, 1086MO and LBA51 (PDF Format)
Mini oral session – Melanoma and other skin tumours LBA50 – Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours LBA50 – Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial (PDF Format)
Mini oral session – Melanoma and other skin tumours LBA51 – Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours LBA51 – Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma (PDF Format)
Mini oral session – Melanoma and other skin tumours LBA52 – A randomized phase Ib II study of the selective small molecule AXL inhibitor bemcentinib (Video MP4 Format)
Mini oral session – Melanoma and other skin tumours LBA52 – A randomized phase Ib II study of the selective small molecule AXL inhibitor bemcentinib (PDF Format)
Mini oral session – NETs and endocrine tumours 1183MO – Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 1183MO – Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable (PDF Format)
Mini oral session – NETs and endocrine tumours 1184MO – Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3) (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 1184MO – Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3) (PDF Format)
Mini oral session – NETs and endocrine tumours 1185MO – Activity and safety of avelumab alone or in combination with cabozantinib in patients (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 1185MO – Activity and safety of avelumab alone or in combination with cabozantinib in patients (PDF Format)
Mini oral session – NETs and endocrine tumours 1186MO – A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 1186MO – A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PDF Format)
Mini oral session – NETs and endocrine tumours 1187MO – Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 1187MO – Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France (PDF Format)
Mini oral session – NETs and endocrine tumours 2211MO – Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 2211MO – Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers (PDF Format)
Mini oral session – NETs and endocrine tumours 2212MO – Major secondary outcomes in the multicentre noninferiority randomised trial IoN (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 2212MO – Major secondary outcomes in the multicentre noninferiority randomised trial IoN (PDF Format)
Mini oral session – NETs and endocrine tumours 725MO – Phase I trial of the DLL3 CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours (Video MP4 Format)
Mini oral session – NETs and endocrine tumours 725MO – Phase I trial of the DLL3 CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours (PDF Format)
Mini oral session – NETs and endocrine tumours Invited Discussant 1184MO, 1185MO and 725MO (Video MP4 Format)
Mini oral session – NETs and endocrine tumours Invited Discussant 1184MO, 1185MO and 725MO (PDF Format)
Mini oral session – NETs and endocrine tumours Invited Discussant 1186MO, 2212MO and 1187MO (Video MP4 Format)
Mini oral session – NETs and endocrine tumours Invited Discussant 1186MO, 2212MO and 1187MO (PDF Format)
Mini oral session – NETs and endocrine tumours Invited Discussant 2211MO and 1183MO (Video MP4 Format)
Mini oral session – NETs and endocrine tumours Invited Discussant 2211MO and 1183MO (PDF Format)
Mini oral session – Policy and preventive strategies 1692MO – Is project Orbis successful The Swiss perspective (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1692MO – Is project Orbis successful The Swiss perspective (PDF Format)
Mini oral session – Policy and preventive strategies 1693MO – The high burden of long-term and late health-related problems among adolescent and young adult (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1693MO – The high burden of long-term and late health-related problems among adolescent and young adult (PDF Format)
Mini oral session – Policy and preventive strategies 1694MO – Socio-economic consequences among adolescent and young adult cancer patients (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1694MO – Socio-economic consequences among adolescent and young adult cancer patients (PDF Format)
Mini oral session – Policy and preventive strategies 1695MO – Cancer care during armed conflict- Factors associated with adult patient transfer for treatment abroad during the war in Ukraine (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1695MO – Cancer care during armed conflict- Factors associated with adult patient transfer for treatment abroad during the war in Ukraine (PDF Format)
Mini oral session – Policy and preventive strategies 1696MO – Partial orphan cancer drugs- FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1696MO – Partial orphan cancer drugs- FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending (PDF Format)
Mini oral session – Policy and preventive strategies 1697MO – Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1697MO – Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases (PDF Format)
Mini oral session – Policy and preventive strategies 1698MO – E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1698MO – E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening (PDF Format)
Mini oral session – Policy and preventive strategies 1699MO – Intervening factors for participation and non-participation in colorectal cancer screening in Spain (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1699MO – Intervening factors for participation and non-participation in colorectal cancer screening in Spain (PDF Format)
Mini oral session – Policy and preventive strategies 1700MO – Knowledge of cancer risk factors and risk-reduction in 20 high- and middle-income countries (PDF Format)
Mini oral session – Policy and preventive strategies 1759MO – Clinical breast examination for early diagnosis of breast cancer- An Egyptian nationwide study (Video MP4 Format)
Mini oral session – Policy and preventive strategies 1759MO – Clinical breast examination for early diagnosis of breast cancer- An Egyptian nationwide study (PDF Format)
Mini oral session – Policy and preventive strategies Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO (Video MP4 Format)
Mini oral session – Policy and preventive strategies Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO (PDF Format)
Mini oral session – Policy and preventive strategies Invited Discussant 1698MO, 1699MO and 1700MO (Video MP4 Format)
Mini oral session – Policy and preventive strategies Invited Discussant 1698MO, 1699MO and 1700MO (PDF Format)
Mini oral session – Policy and preventive strategies Invited Discussant 1759MO, 1696MO and 1697MO (Video MP4 Format)
Mini oral session – Policy and preventive strategies Invited Discussant 1759MO, 1696MO and 1697MO (PDF Format)
Mini oral session – Sarcoma 1914MO – The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib (Video MP4 Format)
Mini oral session – Sarcoma 1914MO – The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib (PDF Format)
Mini oral session – Sarcoma 1915MO – Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) (Video MP4 Format)
Mini oral session – Sarcoma 1915MO – Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) (PDF Format)
Mini oral session – Sarcoma 1916MO – A first-in-human phase I trial of NB003, a potent and selective KIT PDGFRa inhibitor (Video MP4 Format)
Mini oral session – Sarcoma 1916MO – A first-in-human phase I trial of NB003, a potent and selective KIT PDGFRa inhibitor (PDF Format)
Mini oral session – Sarcoma 1917MO – CHAPTER-GIST-101- A phase I study of pimitespib combined with imatinib in patients (Video MP4 Format)
Mini oral session – Sarcoma 1917MO – CHAPTER-GIST-101- A phase I study of pimitespib combined with imatinib in patients (PDF Format)
Mini oral session – Sarcoma 1918MO – Circulating tumor DNA in relation to tumor volume in gastro-intestinal stromal tumors (Video MP4 Format)
Mini oral session – Sarcoma 1918MO – Circulating tumor DNA in relation to tumor volume in gastro-intestinal stromal tumors (PDF Format)
Mini oral session – Sarcoma 1919MO – Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma (Video MP4 Format)
Mini oral session – Sarcoma 1919MO – Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma (PDF Format)
Mini oral session – Sarcoma 1920MO – Regomune- A phase II study of regorafenib + avelumab in solid tumors – Results of the advanced (Video MP4 Format)
Mini oral session – Sarcoma 1920MO – Regomune- A phase II study of regorafenib + avelumab in solid tumors – Results of the advanced (PDF Format)
Mini oral session – Sarcoma 1921MO – Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies (Video MP4 Format)
Mini oral session – Sarcoma 1921MO – Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies (PDF Format)
Mini oral session – Sarcoma Invited Discussant 1914MO and 1915MO (Video MP4 Format)
Mini oral session – Sarcoma Invited Discussant 1914MO and 1915MO (PDF Format)
Mini oral session – Sarcoma Invited Discussant 1916MO, 1917MO and 1918MO (Video MP4 Format)
Mini oral session – Sarcoma Invited Discussant 1916MO, 1917MO and 1918MO (PDF Format)
Mini oral session – Sarcoma Invited Discussant 1919MO, 1920MO and 1921MO (Video MP4 Format)
Mini oral session – Sarcoma Invited Discussant 1919MO, 1920MO and 1921MO (PDF Format)
Mini oral session – Supportive and palliative care 1592MO – Anticancer therapy at the end-of-life- A cluster-randomized trial (Video MP4 Format)
Mini oral session – Supportive and palliative care 1592MO – Anticancer therapy at the end-of-life- A cluster-randomized trial (PDF Format)
Mini oral session – Supportive and palliative care 1593MO – Combined early palliative care in patients with non small cell lung cancer (Video MP4 Format)
Mini oral session – Supportive and palliative care 1593MO – Combined early palliative care in patients with non small cell lung cancer (PDF Format)
Mini oral session – Supportive and palliative care 1843MO – The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial) (Video MP4 Format)
Mini oral session – Supportive and palliative care 1843MO – The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial) (PDF Format)
Mini oral session – Supportive and palliative care 1844MO – Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive (Video MP4 Format)
Mini oral session – Supportive and palliative care 1844MO – Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive (PDF Format)
Mini oral session – Supportive and palliative care 2032MO – Correlation of safety and efficacy in atezolizumab therapy across indications (Video MP4 Format)
Mini oral session – Supportive and palliative care 2032MO – Correlation of safety and efficacy in atezolizumab therapy across indications (PDF Format)
Mini oral session – Supportive and palliative care 2033MO – The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (Video MP4 Format)
Mini oral session – Supportive and palliative care 2033MO – The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (PDF Format)
Mini oral session – Supportive and palliative care 2034MO – EAGER- A randomized, controlled, multicenter trial of electro-acupuncture in gastric cancer patients (Video MP4 Format)
Mini oral session – Supportive and palliative care 2034MO – EAGER- A randomized, controlled, multicenter trial of electro-acupuncture in gastric cancer patients (PDF Format)
Mini oral session – Supportive and palliative care Invited Discussant 1592MO, 1593MO and 2034MO (Video MP4 Format)
Mini oral session – Supportive and palliative care Invited Discussant 1592MO, 1593MO and 2034MO (PDF Format)
Mini oral session – Supportive and palliative care Invited Discussant 2032MO, 1843MO, 2033MO (Video MP4 Format)
Mini oral session – Supportive and palliative care Invited Discussant 2032MO, 1843MO, 2033MO (PDF Format)
Mini oral session – Supportive and palliative care Invited Discussant LBA96, LBA97 and 1844MO (Video MP4 Format)
Mini oral session – Supportive and palliative care Invited Discussant LBA96, LBA97 and 1844MO (PDF Format)
Mini oral session – Supportive and palliative care LBA96 – Roxadustat for chemotherapy-induced anemia in patients with non-myeloid malignancies (Video MP4 Format)
Mini oral session – Supportive and palliative care LBA96 – Roxadustat for chemotherapy-induced anemia in patients with non-myeloid malignancies (PDF Format)
Mini oral session – Supportive and palliative care LBA97 – Olanzapine for the prevention of chemotherapy induced nausea vomiting in patients receiving (Video MP4 Format)
Mini oral session – Supportive and palliative care LBA97 – Olanzapine for the prevention of chemotherapy induced nausea vomiting in patients receiving (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1512MO – Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1512MO – Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1513MO – A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1513MO – A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 945MO – AdvanTIG-206 Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 945MO – AdvanTIG-206 Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 94MO – Advanced extrahepatic cholangiocarcinoma- Post-hoc analysis of the ABC-01, -02 and -03 clinical trials (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 94MO – Advanced extrahepatic cholangiocarcinoma- Post-hoc analysis of the ABC-01, -02 and -03 clinical trials (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 95MO – Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive 95MO – Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 945MO, 94MO and 95MO (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 945MO, 94MO and 95MO (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA78 and 1512MO (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA78 and 1512MO (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA79, LBA80 and 1513MO (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA79, LBA80 and 1513MO (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA81 and LBA82 (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA81 and LBA82 (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA78 – Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA78 – Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA79 – GEMSTONE-303- Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA79 – GEMSTONE-303- Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA80 – Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA80 – Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA81 – Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA81 – Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (PDF Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA82 – Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab (Video MP4 Format)
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA82 – Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1262MO – Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1262MO – Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1263MO – The impact of PET-CT and brain MRI for metastasis detection among patients with T1-stage lung cancer (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1263MO – The impact of PET-CT and brain MRI for metastasis detection among patients with T1-stage lung cancer (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1988MO – Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1988MO – Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1989MO – Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC) (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1989MO – Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC) (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1990MO – Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC) (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1990MO – Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC) (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1262MO and 1263MO (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1262MO and 1263MO (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1988MO, 1989MO and 1990MO (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1988MO, 1989MO and 1990MO (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA99 and LBA93 (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA99 and LBA93 (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA93 – EXTENTORCH- A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA93 – EXTENTORCH- A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy (PDF Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA99 – First survival data from the NIPU trial- A randomised, open-label, phase II study evaluating (Video MP4 Format)
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA99 – First survival data from the NIPU trial- A randomised, open-label, phase II study evaluating (PDF Format)
Mini oral session 1 – NSCLC, metastatic 1312MO – Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic 1312MO – Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab (PDF Format)
Mini oral session 1 – NSCLC, metastatic 1313MO – Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patient (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic 1313MO – Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patient (PDF Format)
Mini oral session 1 – NSCLC, metastatic 1314MO – TROPION-Lung05- Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic 1314MO – TROPION-Lung05- Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (PDF Format)
Mini oral session 1 – NSCLC, metastatic 1315MO – Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic 1315MO – Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (PDF Format)
Mini oral session 1 – NSCLC, metastatic 1316MO – BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic 1316MO – BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer (PDF Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1312MO and 1313MO (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1312MO and 1313MO (PDF Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1314MO, 1315MO and 1316MO (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1314MO, 1315MO and 1316MO (PDF Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA68 and LBA69 (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA68 and LBA69 (PDF Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA70 and LBA71 (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA70 and LBA71 (PDF Format)
Mini oral session 1 – NSCLC, metastatic LBA68 – FLAURA2- Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic LBA68 – FLAURA2- Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC (PDF Format)
Mini oral session 1 – NSCLC, metastatic LBA69 – Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic LBA69 – Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation (PDF Format)
Mini oral session 1 – NSCLC, metastatic LBA70 – OSIRAM-1- A multicenter, open label, randomized phase II study of osimertinib plus (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic LBA70 – OSIRAM-1- A multicenter, open label, randomized phase II study of osimertinib plus (PDF Format)
Mini oral session 1 – NSCLC, metastatic LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab (Video MP4 Format)
Mini oral session 1 – NSCLC, metastatic LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1264MO – IMpower010- Exploratory analysis of disease-free survival (DFS) by TGFá cancer-associated fibroblast (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1264MO – IMpower010- Exploratory analysis of disease-free survival (DFS) by TGFá cancer-associated fibroblast (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1292MO – A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1292MO – A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1293MO – Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1293MO – Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA57, 1264MO, LBA58 and LBA59 (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA57, 1264MO, LBA58 and LBA59 (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA61, 1292MO, LBA62 and 1293MO (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA61, 1292MO, LBA62 and 1293MO (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA57 – Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study- 3-y results by tumor PD-L1 expression (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA57 – Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study- 3-y results by tumor PD-L1 expression (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA58 – Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA58 – Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA59 – Associations of ctDNA clearance and pathological response with neoadjuvant treatment (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA59 – Associations of ctDNA clearance and pathological response with neoadjuvant treatment (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA61 – Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA61 – Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with (PDF Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA62 – Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (Video MP4 Format)
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA62 – Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1317MO – Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1317MO – Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1318MO – First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1318MO – First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1319MO – Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC- Results from HERTHENA-Lung01 (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1319MO – Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC- Results from HERTHENA-Lung01 (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1320MO – Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1320MO – Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1321MO – Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1321MO – Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1322MO – Insights into tumour dissemination and progression using longitudinal Imaging and ctDNA in the TRACERx lung cancer study (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1322MO – Insights into tumour dissemination and progression using longitudinal Imaging and ctDNA in the TRACERx lung cancer study (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1323MO – Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1323MO – Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study (PDF Format)
Mini oral session 2 – NSCLC, metastatic 1324MO – CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC- A LASER301 subset analysis (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic 1324MO – CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC- A LASER301 subset analysis (PDF Format)
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1317MO, 1318MO and 1320MO (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1317MO, 1318MO and 1320MO (PDF Format)
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1319MO, 1321MO and 1324MO (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1319MO, 1321MO and 1324MO (PDF Format)
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1322MO, LBA72 and 1323MO (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1322MO, LBA72 and 1323MO (PDF Format)
Mini oral session 2 – NSCLC, metastatic LBA72 – DARWIN II Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC (Video MP4 Format)
Mini oral session 2 – NSCLC, metastatic LBA72 – DARWIN II Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC (PDF Format)
Mini oral session CNS tumours 502MO – Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma (Video MP4 Format)
Mini oral session CNS tumours 502MO – Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma (PDF Format)
Mini oral session CNS tumours 503MO – Real-world clinical and genomic characterization of gliomas- Predictive and prognostic insights (Video MP4 Format)
Mini oral session CNS tumours 503MO – Real-world clinical and genomic characterization of gliomas- Predictive and prognostic insights (PDF Format)
Mini oral session CNS tumours 504MO – Validation of a spectroscopic liquid biopsy for the earlier detection of brain cancer (Video MP4 Format)
Mini oral session CNS tumours 504MO – Validation of a spectroscopic liquid biopsy for the earlier detection of brain cancer (PDF Format)
Mini oral session CNS tumours 505MO – A phase 0 Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients (Video MP4 Format)
Mini oral session CNS tumours 505MO – A phase 0 Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients (PDF Format)
Mini oral session CNS tumours 506MO – A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) (Video MP4 Format)
Mini oral session CNS tumours 506MO – A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) (PDF Format)
Mini oral session CNS tumours 507MO – REGOMA-OS- A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients (Video MP4 Format)
Mini oral session CNS tumours 507MO – REGOMA-OS- A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients (PDF Format)
Mini oral session CNS tumours 508MO – Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition (Video MP4 Format)
Mini oral session CNS tumours 508MO – Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition (PDF Format)
Mini oral session CNS tumours Invited Discussant 502MO, 503MO and 504MO (Video MP4 Format)
Mini oral session CNS tumours Invited Discussant 502MO, 503MO and 504MO (PDF Format)
Mini oral session CNS tumours Invited Discussant 505MO and 506MO (Video MP4 Format)
Mini oral session CNS tumours Invited Discussant 505MO and 506MO (PDF Format)
Mini oral session CNS tumours Invited Discussant 507MO and 508MO (Video MP4 Format)
Mini oral session CNS tumours Invited Discussant 507MO and 508MO (PDF Format)
Mini oral session Developmental therapeutics 657MO – Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) (Video MP4 Format)
Mini oral session Developmental therapeutics 657MO – Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) (PDF Format)
Mini oral session Developmental therapeutics 658MO – Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors (Video MP4 Format)
Mini oral session Developmental therapeutics 658MO – Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors (PDF Format)
Mini oral session Developmental therapeutics 659MO – Preliminary results from a phase I II study of 9MW2821 (Video MP4 Format)
Mini oral session Developmental therapeutics 659MO – Preliminary results from a phase I II study of 9MW2821 (PDF Format)
Mini oral session Developmental therapeutics 660MO – First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC (Video MP4 Format)
Mini oral session Developmental therapeutics 660MO – First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC (PDF Format)
Mini oral session Developmental therapeutics 661MO – Anti-tumor activity of belvarafenib in combination with cobimetinib in patients (Video MP4 Format)
Mini oral session Developmental therapeutics 661MO – Anti-tumor activity of belvarafenib in combination with cobimetinib in patients (PDF Format)
Mini oral session Developmental therapeutics 662MO – Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068 (Video MP4 Format)
Mini oral session Developmental therapeutics 662MO – Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068 (PDF Format)
Mini oral session Developmental therapeutics Invited Discussant 656MO, 657MO, LBA34 and 658MO (Video MP4 Format)
Mini oral session Developmental therapeutics Invited Discussant 656MO, 657MO, LBA34 and 658MO (PDF Format)
Mini oral session Developmental therapeutics Invited Discussant 659MO and 660MO (Video MP4 Format)
Mini oral session Developmental therapeutics Invited Discussant 659MO and 660MO (PDF Format)
Mini oral session Developmental therapeutics Invited Discussant LBA35, 661MO and 662MO (Video MP4 Format)
Mini oral session Developmental therapeutics Invited Discussant LBA35, 661MO and 662MO (PDF Format)
Mini oral session Developmental therapeutics LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors (Video MP4 Format)
Mini oral session Developmental therapeutics LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors (PDF Format)
Mini oral session Developmental therapeutics LBA35 – BNT211-01- Interim results from a repeat dose escalation study of CLDN6 CAR-T cells (Video MP4 Format)
Mini oral session Developmental therapeutics LBA35 – BNT211-01- Interim results from a repeat dose escalation study of CLDN6 CAR-T cells (PDF Format)
Mini oral session Developmental therapeutics The HER2-targeting ADC SHR-A1811 in HER2-expressing mutated (Video MP4 Format)
Mini oral session Developmental therapeutics The HER2-targeting ADC SHR-A1811 in HER2-expressing mutated (PDF Format)
Molecular evolution of brain metastases and therapeutic implications Discussion led by Chair (Video MP4 Format)
Molecular evolution of brain metastases and therapeutic implications Discussion led by Chair (PDF Format)
Molecular evolution of brain metastases and therapeutic implications Presentation by Expert (Video MP4 Format)
Molecular evolution of brain metastases and therapeutic implications Presentation by Expert (PDF Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Cervical cancer (Video MP4 Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Cervical cancer (PDF Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Conclusions and perspectives (Video MP4 Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Discussion (Video MP4 Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Discussion (PDF Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Endometrial cancer (Video MP4 Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Endometrial cancer (PDF Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Introduction and scientific background (Video MP4 Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Introduction and scientific background (PDF Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Molecular profiling of gynaecological cancers A pathologist’s view (Video MP4 Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Molecular profiling of gynaecological cancers A pathologist’s view (PDF Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Ovarian and rare gynaecological cancers (Video MP4 Format)
Molecular profiling of gynaecological cancers for therapeutic stratification Ovarian and rare gynaecological cancers (PDF Format)
Molecular targets and related treatments Checkpoint inhibitors and Pi3K inhibitors (Video MP4 Format)
Molecular targets and related treatments Checkpoint inhibitors and Pi3K inhibitors (PDF Format)
Molecular targets and related treatments Discussion (Video MP4 Format)
Molecular targets and related treatments Discussion (PDF Format)
Molecular targets and related treatments How to interpret a genomic testing report (Video MP4 Format)
Molecular targets and related treatments How to interpret a genomic testing report (PDF Format)
Molecular targets and related treatments PARP inhibition (Video MP4 Format)
Molecular targets and related treatments PARP inhibition (PDF Format)
Molecular targets and related treatments PSMA targeting (Video MP4 Format)
Molecular targets and related treatments PSMA targeting (PDF Format)
Molecular targets and related treatments Third generation AR targeting (Video MP4 Format)
Molecular targets and related treatments Third generation AR targeting (PDF Format)
More intelligent trial design Conclusions and perspectives (Video MP4 Format)
More intelligent trial design Conclusions and perspectives (PDF Format)
More intelligent trial design De-escalation trials (Video MP4 Format)
More intelligent trial design De-escalation trials (PDF Format)
More intelligent trial design Discussion (Video MP4 Format)
More intelligent trial design Discussion (PDF Format)
More intelligent trial design Introduction and scientific background (Video MP4 Format)
More intelligent trial design Introduction and scientific background (PDF Format)
More intelligent trial design Multi-arm multi-stage (MAMS) trials (Video MP4 Format)
More intelligent trial design Multi-arm multi-stage (MAMS) trials (PDF Format)
More intelligent trial design Pragmatic trials (Video MP4 Format)
More intelligent trial design Pragmatic trials (PDF Format)
More intelligent trial design Trials in low-and middle-income countries (LMIC) (Video MP4 Format)
More intelligent trial design Trials in low-and middle-income countries (LMIC) (PDF Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers Discussion (Video MP4 Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers Discussion (PDF Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers Global access considerations in systemic treatment of genitourinary cancers (Video MP4 Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers Global access considerations in systemic treatment of genitourinary cancers (PDF Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers Interpretation of current peri-operative trial designs and endpoints (Video MP4 Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers Interpretation of current peri-operative trial designs and endpoints (PDF Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of renal cell carcinoma (Video MP4 Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of renal cell carcinoma (PDF Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of urothelial cancer (Video MP4 Format)
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of urothelial cancer (PDF Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Brain metastases- When radiation is (not!) indicated (Video MP4 Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Brain metastases- When radiation is (not!) indicated (PDF Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Glioma beyond TMZ RT (Video MP4 Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Glioma beyond TMZ RT (PDF Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Q&A and Discussion (Video MP4 Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Supportive care- Antiepileptics, steroids and anticoagulation (Video MP4 Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Supportive care- Antiepileptics, steroids and anticoagulation (PDF Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients WHO classification simplified for the busy clinician (Video MP4 Format)
Neuro-Oncology 101- All you need to know to take care of brain tumour patients WHO classification simplified for the busy clinician (PDF Format)
New approaches for technologies, therapies, and surgery Discussion (Video MP4 Format)
New approaches for technologies, therapies, and surgery Discussion (PDF Format)
New approaches for technologies, therapies, and surgery How to decide which mutation to investigate and invest in (Video MP4 Format)
New approaches for technologies, therapies, and surgery How to decide which mutation to investigate and invest in (PDF Format)
New approaches for technologies, therapies, and surgery Identification of new biomarkers in lung cancer (Video MP4 Format)
New approaches for technologies, therapies, and surgery Identification of new biomarkers in lung cancer (PDF Format)
New approaches for technologies, therapies, and surgery Radiation therapies- How do proton beam therapy, stereotactic radiosurgery and gamma knife surgery treat cancer (Video MP4 Format)
New approaches for technologies, therapies, and surgery Radiation therapies- How do proton beam therapy, stereotactic radiosurgery and gamma knife surgery treat cancer (PDF Format)
New approaches for technologies, therapies, and surgery Surgical therapies- What are the new robotic models and how do they support efficient processes in clinical settings (Video MP4 Format)
New approaches for technologies, therapies, and surgery Surgical therapies- What are the new robotic models and how do they support efficient processes in clinical settings (PDF Format)
New mechanisms and drugs for the treatment of patients with sarcomas Conclusions and perspectives (Video MP4 Format)
New mechanisms and drugs for the treatment of patients with sarcomas Discussion (Video MP4 Format)
New mechanisms and drugs for the treatment of patients with sarcomas Discussion (PDF Format)
New mechanisms and drugs for the treatment of patients with sarcomas Introduction and scientific background (Video MP4 Format)
New mechanisms and drugs for the treatment of patients with sarcomas Introduction and scientific background (PDF Format)
New mechanisms and drugs for the treatment of patients with sarcomas Multi-facets of antiangiogenic agents (Video MP4 Format)
New mechanisms and drugs for the treatment of patients with sarcomas Multi-facets of antiangiogenic agents (PDF Format)
New mechanisms and drugs for the treatment of patients with sarcomas Novel combinations (Video MP4 Format)
New mechanisms and drugs for the treatment of patients with sarcomas Novel combinations (PDF Format)
New mechanisms and drugs for the treatment of patients with sarcomas Targeting proapoptotic pathways- MDM2 and beyond (Video MP4 Format)
New mechanisms and drugs for the treatment of patients with sarcomas Targeting proapoptotic pathways- MDM2 and beyond (PDF Format)
New targets on the horizon Conclusions and perspectives (Video MP4 Format)
New targets on the horizon Conclusions and perspectives (PDF Format)
New targets on the horizon Discussion (Video MP4 Format)
New targets on the horizon Discussion (PDF Format)
New targets on the horizon Innovative novel delivery of immunotherapeutics (Video MP4 Format)
New targets on the horizon Innovative novel delivery of immunotherapeutics (PDF Format)
New targets on the horizon Introduction and scientific background (Video MP4 Format)
New targets on the horizon Introduction and scientific background (PDF Format)
New targets on the horizon Mutant specific inhibitors (Video MP4 Format)
New targets on the horizon Mutant specific inhibitors (PDF Format)
New targets on the horizon Peptide-based cancer vaccines (Video MP4 Format)
New targets on the horizon Peptide-based cancer vaccines (PDF Format)
New targets on the horizon POLTheta inhibitors and USP1 inhibitors for BRCA-deficient cancers (Video MP4 Format)
New targets on the horizon POLTheta inhibitors and USP1 inhibitors for BRCA-deficient cancers (PDF Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Conclusions and perspectives (Video MP4 Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Discussion (Video MP4 Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Discussion (PDF Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Drug sensitivity testing in blood cancer (Video MP4 Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Drug sensitivity testing in blood cancer (PDF Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing How novel profiling methods impact trial design (Video MP4 Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing How novel profiling methods impact trial design (PDF Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Introduction and scientific background (Video MP4 Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Introduction and scientific background (PDF Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Liquid biopsy in lymphoma (Video MP4 Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Liquid biopsy in lymphoma (PDF Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Multi-omic profiling in lymphoid neoplasms (Video MP4 Format)
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Multi-omic profiling in lymphoid neoplasms (PDF Format)
Novel targets, therapies and toxicities in genitourinary cancers Advances in the molecular understanding of GU cancers- The next generation of therapeutic targets (Video MP4 Format)
Novel targets, therapies and toxicities in genitourinary cancers Advances in the molecular understanding of GU cancers- The next generation of therapeutic targets (PDF Format)
Novel targets, therapies and toxicities in genitourinary cancers Antibody drug conjugates and FGFR-directed therapies- New toxicities (Video MP4 Format)
Novel targets, therapies and toxicities in genitourinary cancers Antibody drug conjugates and FGFR-directed therapies- New toxicities (PDF Format)
Novel targets, therapies and toxicities in genitourinary cancers Conclusions and perspectives (Video MP4 Format)
Novel targets, therapies and toxicities in genitourinary cancers Conclusions and perspectives (PDF Format)
Novel targets, therapies and toxicities in genitourinary cancers Discussion (Video MP4 Format)
Novel targets, therapies and toxicities in genitourinary cancers Discussion (PDF Format)
Novel targets, therapies and toxicities in genitourinary cancers Introduction and scientific background (Video MP4 Format)
Novel targets, therapies and toxicities in genitourinary cancers Introduction and scientific background (PDF Format)
Novel targets, therapies and toxicities in genitourinary cancers Prediction of toxicity in current systemic treatment of genitourinary cancers (Video MP4 Format)
Novel targets, therapies and toxicities in genitourinary cancers Prediction of toxicity in current systemic treatment of genitourinary cancers (PDF Format)
Novel targets, therapies and toxicities in genitourinary cancers Screening new agents in “window of opportunity” neoadjuvant trials (Video MP4 Format)
Novel targets, therapies and toxicities in genitourinary cancers Screening new agents in “window of opportunity” neoadjuvant trials (PDF Format)
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Bringing change with TTFields therapy in ovarian cancer (Video MP4 Format)
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Evolving role of TTFields therapy in NSCLC (Video MP4 Format)
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Fireside chat (Video MP4 Format)
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Practice changing experience of TTFields therapy in Glioblastoma (Video MP4 Format)
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Welcome (Video MP4 Format)
Oncology drug trials- How can we bring true value for patients Challenges, pitfalls and the way forward- Investigator’s perspective (Video MP4 Format)
Oncology drug trials- How can we bring true value for patients Challenges, pitfalls and the way forward- Investigator’s perspective (PDF Format)
Oncology drug trials- How can we bring true value for patients Clinical trials in oncology- What really matters to patients. (Video MP4 Format)
Oncology drug trials- How can we bring true value for patients Clinical trials in oncology- What really matters to patients (PDF Format)
Oncology drug trials- How can we bring true value for patients Q&A and Discussion (Video MP4 Format)
Oncology drug trials- How can we bring true value for patients Q&A and Discussion (PDF Format)
Oncology drug trials- How can we bring true value for patients Walking the tightrope without losing sight of the patient (Video MP4 Format)
Oncology drug trials- How can we bring true value for patients Walking the tightrope without losing sight of the patient (PDF Format)
Oncology drug trials- How can we bring true value for patients “Value” and what it really means for new cancer drugs (Video MP4 Format)
Oncology drug trials- How can we bring true value for patients “Value” and what it really means for new cancer drugs (PDF Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Conclusions and perspectives (Video MP4 Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Discussion (Video MP4 Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Discussion (PDF Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Duration of IO treatment (Video MP4 Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Duration of IO treatment (PDF Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge How to overcome IO resistance- New approaches (Video MP4 Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge How to overcome IO resistance- New approaches (PDF Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Immunotherapy re-challenge- Who, when and why (Video MP4 Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Immunotherapy re-challenge- Who, when and why (PDF Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Introduction and scientific background (Video MP4 Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Introduction and scientific background (PDF Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge When and how to combine PD-1 PD-L1 (Video MP4 Format)
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge When and how to combine PD-1 PD-L1 (PDF Format)
Open questions in the management of mesothelioma Biomarker-selected therapy- Progress or delusion (Video MP4 Format)
Open questions in the management of mesothelioma Biomarker-selected therapy- Progress or delusion (PDF Format)
Open questions in the management of mesothelioma Discussion (Video MP4 Format)
Open questions in the management of mesothelioma Discussion (PDF Format)
Open questions in the management of mesothelioma Introduction and scientific background (Video MP4 Format)
Open questions in the management of mesothelioma Introduction and scientific background (PDF Format)
Open questions in the management of mesothelioma Preoperative or postoperative radiation for mesothelioma (Video MP4 Format)
Open questions in the management of mesothelioma Preoperative or postoperative radiation for mesothelioma (PDF Format)
Open questions in the management of mesothelioma What is the optimal first-line treatment (Video MP4 Format)
Open questions in the management of mesothelioma What is the optimal first-line treatment (PDF Format)
Open questions in the management of mesothelioma When and when not to operate (Video MP4 Format)
Open questions in the management of mesothelioma When and when not to operate (PDF Format)
Opening session Closure of the Opening Ceremony (Video MP4 Format)
Opening session Closure of the Opening Ceremony (PDF Format)
Opening session ESMO Award 2023 (Video MP4 Format)
Opening session ESMO Award 2023 (PDF Format)
Opening session ESMO Award for Translational Research 2023 (Video MP4 Format)
Opening session ESMO Award for Translational Research 2023 (PDF Format)
Opening session ESMO Lifetime Achievement Award 2023 (Video MP4 Format)
Opening session ESMO Lifetime Achievement Award 2023 (PDF Format)
Opening session ESMO Women for Oncology Award 2023 (Video MP4 Format)
Opening session ESMO Women for Oncology Award 2023 (PDF Format)
Opening session Presentation of the ESMO awards 2023 (Video MP4 Format)
Opening session Presentation of the ESMO awards 2023 (PDF Format)
Opening session Scientific Chair address (Video MP4 Format)
Opening session Scientific Chair address (PDF Format)
Opening session Welcome and Presidential address (Video MP4 Format)
Opening session Welcome and Presidential address (PDF Format)
Opening session World Health Organisation (WHO) (Video MP4 Format)
Opening session World Health Organisation (WHO) (PDF Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Discussion (Video MP4 Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 HER2+ breast cancer (Video MP4 Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 HER2+ breast cancer (PDF Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Introduction (Video MP4 Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Introduction (PDF Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Luminal-like breast cancer (Video MP4 Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Luminal-like breast cancer (PDF Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Triple-negative breast cancer (Video MP4 Format)
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Triple-negative breast cancer (PDF Format)
Optimising overall survival in advanced renal cancer Data from sequencing trials and new therapeutic targets (Video MP4 Format)
Optimising overall survival in advanced renal cancer Data from sequencing trials and new therapeutic targets (PDF Format)
Optimising overall survival in advanced renal cancer Discussion (Video MP4 Format)
Optimising overall survival in advanced renal cancer Discussion (PDF Format)
Optimising overall survival in advanced renal cancer Evolving frontline treatment paradigms (Video MP4 Format)
Optimising overall survival in advanced renal cancer Evolving frontline treatment paradigms (PDF Format)
Optimising overall survival in advanced renal cancer What is the role of localised therapies in metastatic RCC (Video MP4 Format)
Optimising overall survival in advanced renal cancer What is the role of localised therapies in metastatic RCC (PDF Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Case Condition presentation (Video MP4 Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Case Condition presentation (PDF Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Discussion (Video MP4 Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Discussion (PDF Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Endoscopic management of obstructive jaundice- What clinicians should know (Video MP4 Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Endoscopic management of obstructive jaundice- What clinicians should know (PDF Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Malignant ascites (Video MP4 Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Malignant ascites (PDF Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Nutrition and exercise (Video MP4 Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Nutrition and exercise (PDF Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Pain management and palliative care (Video MP4 Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Pain management and palliative care (PDF Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Radiotherapy (Video MP4 Format)
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Radiotherapy (PDF Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Contra (Video MP4 Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Contra (PDF Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all First voting (Video MP4 Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all First voting (PDF Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Perspective from the Chair (Video MP4 Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Perspective from the Chair (PDF Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Pro (Video MP4 Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Pro (PDF Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Second voting (Video MP4 Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Second voting (PDF Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Welcome and “set the scene” (Video MP4 Format)
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Welcome and “set the scene” (PDF Format)
People at the centre of cancer care Advocating for cancer care in Armenia (Video MP4 Format)
People at the centre of cancer care Advocating for cancer care in Armenia (PDF Format)
People at the centre of cancer care Discussion (Video MP4 Format)
People at the centre of cancer care Patient satisfaction during treatment and after care (Video MP4 Format)
People at the centre of cancer care Patient satisfaction during treatment and after care (PDF Format)
People at the centre of cancer care People at the centre (Video MP4 Format)
People at the centre of cancer care People at the centre (PDF Format)
People at the centre of cancer care Personalised treatment- Reflections on CAR-T therapy (Video MP4 Format)
People at the centre of cancer care Personalised treatment- Reflections on CAR-T therapy (PDF Format)
Pregnancy after breast cancer- Is it safe First voting (Video MP4 Format)
Pregnancy after breast cancer- Is it safe First voting (PDF Format)
Pregnancy after breast cancer- Is it safe No (Video MP4 Format)
Pregnancy after breast cancer- Is it safe No (PDF Format)
Pregnancy after breast cancer- Is it safe Perspective from the Chair (Video MP4 Format)
Pregnancy after breast cancer- Is it safe Perspective from the Chair (PDF Format)
Pregnancy after breast cancer- Is it safe Second voting (Video MP4 Format)
Pregnancy after breast cancer- Is it safe Second voting (PDF Format)
Pregnancy after breast cancer- Is it safe Welcome and “set the scene” (Video MP4 Format)
Pregnancy after breast cancer- Is it safe Welcome and “set the scene” (PDF Format)
Pregnancy after breast cancer- Is it safe Yes (Video MP4 Format)
Pregnancy after breast cancer- Is it safe Yes (PDF Format)
Presidential 1 Invited Discussant LBA1 and LBA2 (Video MP4 Format)
Presidential 1 Invited Discussant LBA1 and LBA2 (PDF Format)
Presidential 1 Invited Discussant LBA3 (Video MP4 Format)
Presidential 1 Invited Discussant LBA3 (PDF Format)
Presidential 1 Invited Discussant LBA4 and LBA5 (Video MP4 Format)
Presidential 1 Invited Discussant LBA4 and LBA5 (PDF Format)
Presidential 1 LBA1 – CheckMate 77T- Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (Video MP4 Format)
Presidential 1 LBA1 – CheckMate 77T- Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (PDF Format)
Presidential 1 LBA2 – ALINA- Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ (Video MP4 Format)
Presidential 1 LBA2 – ALINA- Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ (PDF Format)
Presidential 1 LBA3 – Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase (Video MP4 Format)
Presidential 1 LBA3 – Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase (PDF Format)
Presidential 1 LBA4 – Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC (Video MP4 Format)
Presidential 1 LBA4 – Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC (PDF Format)
Presidential 1 LBA5 – Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 (Video MP4 Format)
Presidential 1 LBA5 – Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 (PDF Format)
Presidential 2 Invited Discussant LBA10 (Video MP4 Format)
Presidential 2 Invited Discussant LBA10 (PDF Format)
Presidential 2 Invited Discussant LBA6 and LBA7 (Video MP4 Format)
Presidential 2 Invited Discussant LBA6 and LBA7 (PDF Format)
Presidential 2 Invited Discussant LBA8 and LBA9 (Video MP4 Format)
Presidential 2 Invited Discussant LBA8 and LBA9 (PDF Format)
Presidential 2 LBA10 – Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated (Video MP4 Format)
Presidential 2 LBA10 – Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated (PDF Format)
Presidential 2 LBA6 – EV-302 KEYNOTE-A39- Open-label, randomized phase III study of enfortumab vedotin in combination (Video MP4 Format)
Presidential 2 LBA6 – EV-302 KEYNOTE-A39- Open-label, randomized phase III study of enfortumab vedotin in combination (PDF Format)
Presidential 2 LBA7 – Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated (Video MP4 Format)
Presidential 2 LBA7 – Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated (PDF Format)
Presidential 2 LBA8 – A randomised phase III trial of induction chemotherapy followed by chemoradiation compared (Video MP4 Format)
Presidential 2 LBA8 – A randomised phase III trial of induction chemotherapy followed by chemoradiation compared (PDF Format)
Presidential 2 LBA9 – innovaTV 301 ENGOT-cx12 GOG-3057- A global, randomized, open-label, phase III study of tisotumab (Video MP4 Format)
Presidential 2 LBA9 – innovaTV 301 ENGOT-cx12 GOG-3057- A global, randomized, open-label, phase III study of tisotumab (PDF Format)
Presidential 2 Q&A (Video MP4 Format)
Presidential 3 Invited Discussant LBA11 and LBA12 (Video MP4 Format)
Presidential 3 Invited Discussant LBA11 and LBA12 (PDF Format)
Presidential 3 Invited Discussant LBA13 (Video MP4 Format)
Presidential 3 Invited Discussant LBA13 (PDF Format)
Presidential 3 Invited Discussant LBA14 and LBA15 (Video MP4 Format)
Presidential 3 Invited Discussant LBA14 and LBA15 (PDF Format)
Presidential 3 LBA11 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic (Video MP4 Format)
Presidential 3 LBA11 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic (PDF Format)
Presidential 3 LBA12 – Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic (Video MP4 Format)
Presidential 3 LBA12 – Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic (PDF Format)
Presidential 3 LBA13 – Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) (Video MP4 Format)
Presidential 3 LBA13 – Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) (PDF Format)
Presidential 3 LBA14 – Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated (Video MP4 Format)
Presidential 3 LBA14 – Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated (PDF Format)
Presidential 3 LBA15 – Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated (Video MP4 Format)
Presidential 3 LBA15 – Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated (PDF Format)
Presidential 3 Q&A (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA17, LBA18 and LBA19 (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA17, LBA18 and LBA19 (PDF Format)
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA20 and LBA21 (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA20 and LBA21 (PDF Format)
Proffered Paper session – Breast cancer, early stage LBA17 – Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage LBA17 – Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer (PDF Format)
Proffered Paper session – Breast cancer, early stage LBA18 – Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage LBA18 – Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage (PDF Format)
Proffered Paper session – Breast cancer, early stage LBA19 – Event-free survival (EFS) analysis of neoadjuvant taxane carboplatin with or without (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage LBA19 – Event-free survival (EFS) analysis of neoadjuvant taxane carboplatin with or without (PDF Format)
Proffered Paper session – Breast cancer, early stage LBA20 – A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage LBA20 – A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (PDF Format)
Proffered Paper session – Breast cancer, early stage LBA21 – KEYNOTE-756- Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage LBA21 – KEYNOTE-756- Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) (PDF Format)
Proffered Paper session – Breast cancer, early stage Q&A 1 (Video MP4 Format)
Proffered Paper session – Breast cancer, early stage Q&A 1 (PDF Format)
Proffered Paper session – Breast cancer, early stage Q&A 2 (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic 376O – Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2 (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic 376O – Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2 (PDF Format)
Proffered Paper session – Breast cancer, metastatic 377O – A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic 377O – A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) (PDF Format)
Proffered Paper session – Breast cancer, metastatic 378O – Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic 378O – Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) (PDF Format)
Proffered Paper session – Breast cancer, metastatic 381O – First-in-human phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic 381O – First-in-human phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors (PDF Format)
Proffered Paper session – Breast cancer, metastatic Invited Discussant 377O and 378O (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic Invited Discussant 377O and 378O (PDF Format)
Proffered Paper session – Breast cancer, metastatic Invited Discussant 381O and 376O (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic Invited Discussant 381O and 376O (PDF Format)
Proffered Paper session – Breast cancer, metastatic Q&A 1 (Video MP4 Format)
Proffered Paper session – Breast cancer, metastatic Q&A 2 (Video MP4 Format)
Proffered Paper session – CNS tumours 499O – A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric (Video MP4 Format)
Proffered Paper session – CNS tumours 499O – A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric (PDF Format)
Proffered Paper session – CNS tumours 500O – Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) (Video MP4 Format)
Proffered Paper session – CNS tumours 500O – Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) (PDF Format)
Proffered Paper session – CNS tumours 501O – Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed (Video MP4 Format)
Proffered Paper session – CNS tumours 501O – Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed (PDF Format)
Proffered Paper session – CNS tumours Invited Discussant 498O (Video MP4 Format)
Proffered Paper session – CNS tumours Invited Discussant 498O (PDF Format)
Proffered Paper session – CNS tumours Invited Discussant 499O, 500O and 501O (Video MP4 Format)
Proffered Paper session – CNS tumours Invited Discussant 499O, 500O and 501O (PDF Format)
Proffered Paper session – CNS tumours Q&A 1 (Video MP4 Format)
Proffered Paper session – CNS tumours Q&A 2 (Video MP4 Format)
Proffered Paper session – CNS tumours Q&A 2 (PDF Format)
Proffered Paper session – Developmental therapeutics 652O – Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) (Video MP4 Format)
Proffered Paper session – Developmental therapeutics 652O – Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) (PDF Format)
Proffered Paper session – Developmental therapeutics 653O – Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS (Video MP4 Format)
Proffered Paper session – Developmental therapeutics 653O – Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS (PDF Format)
Proffered Paper session – Developmental therapeutics 654O – Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring (Video MP4 Format)
Proffered Paper session – Developmental therapeutics 654O – Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring (PDF Format)
Proffered Paper session – Developmental therapeutics 655O – Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7 (Video MP4 Format)
Proffered Paper session – Developmental therapeutics 655O – Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7 (PDF Format)
Proffered Paper session – Developmental therapeutics Invited Discussant 652O, 653O and LBA33 (Video MP4 Format)
Proffered Paper session – Developmental therapeutics Invited Discussant 652O, 653O and LBA33 (PDF Format)
Proffered Paper session – Developmental therapeutics Invited Discussant 654O and 655O (Video MP4 Format)
Proffered Paper session – Developmental therapeutics Invited Discussant 654O and 655O (PDF Format)
Proffered Paper session – Developmental therapeutics LBA33 – A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid (Video MP4 Format)
Proffered Paper session – Developmental therapeutics LBA33 – A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid (PDF Format)
Proffered Paper session – Developmental therapeutics Q&A 1 (Video MP4 Format)
Proffered Paper session – Developmental therapeutics Q&A 2 (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate 1764O – Timing of radiotherapy (RT) after radical prostatectomy (RP)- Final results of RADICALS RT randomised controlled trial (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate 1764O – Timing of radiotherapy (RT) after radical prostatectomy (RP)- Final results of RADICALS RT randomised controlled trial (PDF Format)
Proffered Paper session – Genitourinary tumours, prostate 1765O – Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate 1765O – Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune (PDF Format)
Proffered Paper session – Genitourinary tumours, prostate 1770O – Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate 1770O – Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for (PDF Format)
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant 1764O and 1765O (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant 1764O and 1765O (PDF Format)
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant LBA84 and 1770O (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant LBA84 and 1770O (PDF Format)
Proffered Paper session – Genitourinary tumours, prostate LBA84 – Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate LBA84 – Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (PDF Format)
Proffered Paper session – Genitourinary tumours, prostate Q&A 1 (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate Q&A 1 (PDF Format)
Proffered Paper session – Genitourinary tumours, prostate Q&A 2 (Video MP4 Format)
Proffered Paper session – Genitourinary tumours, prostate Q&A 2 (PDF Format)
Proffered paper session – Haematological malignancies 822O – Activation of ?9ë2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed refractory (Video MP4 Format)
Proffered paper session – Haematological malignancies 822O – Activation of ?9ë2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed refractory (PDF Format)
Proffered paper session – Haematological malignancies 823O – Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell (Video MP4 Format)
Proffered paper session – Haematological malignancies 823O – Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell (PDF Format)
Proffered paper session – Haematological malignancies 824O – Treatment and survival in patients with localized primary ocular adnexal MALT lymphoma- A large bicentric cohort study (Video MP4 Format)
Proffered paper session – Haematological malignancies 824O – Treatment and survival in patients with localized primary ocular adnexal MALT lymphoma- A large bicentric cohort study (PDF Format)
Proffered paper session – Haematological malignancies 825O – Genomic traits of therapeutic response to anti-PD-1 therapy in peripheral T cell lymphoma (Video MP4 Format)
Proffered paper session – Haematological malignancies 825O – Genomic traits of therapeutic response to anti-PD-1 therapy in peripheral T cell lymphoma (PDF Format)
Proffered paper session – Haematological malignancies 826O – A single-arm, multicenter clinical study of radiotherapy combined with toripalimab in stage I II (Video MP4 Format)
Proffered paper session – Haematological malignancies 826O – A single-arm, multicenter clinical study of radiotherapy combined with toripalimab in stage I II (PDF Format)
Proffered paper session – Haematological malignancies Invited Discussant 822O and 823O (Video MP4 Format)
Proffered paper session – Haematological malignancies Invited Discussant 822O and 823O (PDF Format)
Proffered paper session – Haematological malignancies Invited Discussant 824O, 825O and 824O (Video MP4 Format)
Proffered paper session – Haematological malignancies Invited Discussant 824O, 825O and 824O (PDF Format)
Proffered paper session – Haematological malignancies Q&A 1 (Video MP4 Format)
Proffered paper session – Haematological malignancies Q&A 2 (Video MP4 Format)
Proffered Paper session – Head and neck cancer 853O – OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases (Video MP4 Format)
Proffered Paper session – Head and neck cancer 853O – OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases (PDF Format)
Proffered Paper session – Head and neck cancer 854O – INTERLINK-1- Phase III study of cetuximab (CTX) ñ monalizumab (M) in participants (pts) with (Video MP4 Format)
Proffered Paper session – Head and neck cancer 854O – INTERLINK-1- Phase III study of cetuximab (CTX) ñ monalizumab (M) in participants (pts) with (PDF Format)
Proffered Paper session – Head and neck cancer 857O – MACH-EGFR- Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) (Video MP4 Format)
Proffered Paper session – Head and neck cancer 857O – MACH-EGFR- Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) (PDF Format)
Proffered Paper session – Head and neck cancer 858O – Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) (Video MP4 Format)
Proffered Paper session – Head and neck cancer 858O – Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) (PDF Format)
Proffered Paper session – Head and neck cancer Invited Discussant 853O and 857O (Video MP4 Format)
Proffered Paper session – Head and neck cancer Invited Discussant 853O and 857O (PDF Format)
Proffered Paper session – Head and neck cancer Invited Discussant 854MO (Video MP4 Format)
Proffered Paper session – Head and neck cancer Invited Discussant 854MO (PDF Format)
Proffered Paper session – Head and neck cancer Invited Discussant 858O (Video MP4 Format)
Proffered Paper session – Head and neck cancer Invited Discussant 858O (PDF Format)
Proffered Paper session – Head and neck cancer Q&A 1 (Video MP4 Format)
Proffered Paper session – Head and neck cancer Q&A 2 (Video MP4 Format)
Proffered Paper session – Head and neck cancer Q&A 3 (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy 1016O – Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy 1016O – Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC (PDF Format)
Proffered Paper session – Investigational immunotherapy 1017O – NTC-001- A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy 1017O – NTC-001- A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen (PDF Format)
Proffered Paper session – Investigational immunotherapy 1018O – Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy 1018O – Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer (PDF Format)
Proffered Paper session – Investigational immunotherapy 1019O – Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy 1019O – Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) (PDF Format)
Proffered Paper session – Investigational immunotherapy Invited Discussant 1016O (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy Invited Discussant 1016O (PDF Format)
Proffered Paper session – Investigational immunotherapy Invited Discussant 1017O, 1018O and 1019O (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy Invited Discussant 1017O, 1018O and 1019O (PDF Format)
Proffered Paper session – Investigational immunotherapy Q&A 1 (Video MP4 Format)
Proffered Paper session – Investigational immunotherapy Q&A 2 (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours 1081O – ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours 1081O – ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination (PDF Format)
Proffered Paper session – Melanoma and other skin tumours 1082O – Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours 1082O – Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) (PDF Format)
Proffered Paper session – Melanoma and other skin tumours 1085O – Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM) (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours 1085O – Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM) (PDF Format)
Proffered Paper session – Melanoma and other skin tumours Invited Discussant 1082O and 1085O (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours Invited Discussant 1082O and 1085O (PDF Format)
Proffered Paper session – Melanoma and other skin tumours Invited Discussant LBA48, LBA49 and 1081O (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours Invited Discussant LBA48, LBA49 and 1081O (PDF Format)
Proffered Paper session – Melanoma and other skin tumours LBA48 – Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours LBA48 – Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PDF Format)
Proffered Paper session – Melanoma and other skin tumours LBA49 – mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours LBA49 – mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk (PDF Format)
Proffered Paper session – Melanoma and other skin tumours Q&A 1 (Video MP4 Format)
Proffered Paper session – Melanoma and other skin tumours Q&A 2 (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours 1182O – Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours 1182O – Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well (PDF Format)
Proffered Paper session – NETs and endocrine tumours 723O – Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours 723O – Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system (PDF Format)
Proffered Paper session – NETs and endocrine tumours 724O – EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours 724O – EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic (PDF Format)
Proffered Paper session – NETs and endocrine tumours Invited Discussant 723O and LBA53 (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours Invited Discussant 723O and LBA53 (PDF Format)
Proffered Paper session – NETs and endocrine tumours Invited Discussant LBA54, 1182O and 724O (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours Invited Discussant LBA54, 1182O and 724O (PDF Format)
Proffered Paper session – NETs and endocrine tumours LBA53 – Alliance A021602- Phase III, double-blinded study of cabozantinib versus placebo for advanced (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours LBA53 – Alliance A021602- Phase III, double-blinded study of cabozantinib versus placebo for advanced (PDF Format)
Proffered Paper session – NETs and endocrine tumours LBA54 – Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours LBA54 – Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according (PDF Format)
Proffered Paper session – NETs and endocrine tumours Q&A 1 (Video MP4 Format)
Proffered Paper session – NETs and endocrine tumours Q&A 2 (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1261O – Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1261O – Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1291O – Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1291O – Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1261O and LBA56 (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1261O and LBA56 (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA60 and 1291O (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA60 and 1291O (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA98 and LBA92 (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA98 and LBA92 (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA56 – Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA56 – Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA60 – Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA60 – Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA92 – Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC) (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA92 – Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC) (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA98 – Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA98 – Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 1 (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 1 (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 2 (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 2 (PDF Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 3 (Video MP4 Format)
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 3 (PDF Format)
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA63 and LBA64 (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA63 and LBA64 (PDF Format)
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA65, LBA66 and LBA67 (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA65, LBA66 and LBA67 (PDF Format)
Proffered Paper session – NSCLC, metastatic LBA63 – SAPPHIRE- Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic LBA63 – SAPPHIRE- Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously (PDF Format)
Proffered Paper session – NSCLC, metastatic LBA64 – Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar) (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic LBA64 – Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar) (PDF Format)
Proffered Paper session – NSCLC, metastatic LBA65 – KRYSTAL-7- Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na‹ve (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic LBA65 – KRYSTAL-7- Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na‹ve (PDF Format)
Proffered Paper session – NSCLC, metastatic LBA66 – Afatinib versus chemotherapy for treatment-na‹ve non-small cell lung cancer with a sensitizing (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic LBA66 – Afatinib versus chemotherapy for treatment-na‹ve non-small cell lung cancer with a sensitizing (PDF Format)
Proffered Paper session – NSCLC, metastatic LBA67 – A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic LBA67 – A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with (PDF Format)
Proffered Paper session – NSCLC, metastatic Q&A 1 (Video MP4 Format)
Proffered Paper session – NSCLC, metastatic Q&A 2 (Video MP4 Format)
Proffered Paper session – Sarcoma 1913O – A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with (Video MP4 Format)
Proffered Paper session – Sarcoma 1913O – A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with (PDF Format)
Proffered Paper session – Sarcoma Invited Discussant 1913O (Video MP4 Format)
Proffered Paper session – Sarcoma Invited Discussant 1913O (PDF Format)
Proffered Paper session – Sarcoma Invited Discussant LBA89 (Video MP4 Format)
Proffered Paper session – Sarcoma Invited Discussant LBA89 (PDF Format)
Proffered Paper session – Sarcoma Invited Discussant LBA90 and LBA91 (Video MP4 Format)
Proffered Paper session – Sarcoma Invited Discussant LBA90 and LBA91 (PDF Format)
Proffered Paper session – Sarcoma LBA89 – Efficacy and safety findings from MANTRA- A global, randomized, multicenter, phase III study of the (Video MP4 Format)
Proffered Paper session – Sarcoma LBA89 – Efficacy and safety findings from MANTRA- A global, randomized, multicenter, phase III study of the (PDF Format)
Proffered Paper session – Sarcoma LBA90 – A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with (Video MP4 Format)
Proffered Paper session – Sarcoma LBA90 – A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with (PDF Format)
Proffered Paper session – Sarcoma LBA91 – TOMAS2- A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (Video MP4 Format)
Proffered Paper session – Sarcoma LBA91 – TOMAS2- A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (PDF Format)
Proffered Paper session – Sarcoma Q&A 1 (Video MP4 Format)
Proffered Paper session – Sarcoma Q&A 2 (Video MP4 Format)
Proffered Paper session – Sarcoma Q&A 3 (Video MP4 Format)
Proffered Paper session – Supportive and palliative care 2030O – Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for (Video MP4 Format)
Proffered Paper session – Supportive and palliative care 2030O – Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for (PDF Format)
Proffered Paper session – Supportive and palliative care 2031O – Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts) (Video MP4 Format)
Proffered Paper session – Supportive and palliative care 2031O – Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts) (PDF Format)
Proffered Paper session – Supportive and palliative care Invited Discussant 2030O and 2031O (Video MP4 Format)
Proffered Paper session – Supportive and palliative care Invited Discussant LBA94 and LBA95 (Video MP4 Format)
Proffered Paper session – Supportive and palliative care Invited Discussant LBA94 and LBA95 (PDF Format)
Proffered Paper session – Supportive and palliative care LBA94 – Effects of short-term fasting on quality of life as an add-on option during chemotherapy (Video MP4 Format)
Proffered Paper session – Supportive and palliative care LBA94 – Effects of short-term fasting on quality of life as an add-on option during chemotherapy (PDF Format)
Proffered Paper session – Supportive and palliative care LBA95 – Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (Video MP4 Format)
Proffered Paper session – Supportive and palliative care LBA95 – Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (PDF Format)
Proffered Paper session – Supportive and palliative care Q&A 1 (Video MP4 Format)
Proffered Paper session – Supportive and palliative care Q&A 1 (PDF Format)
Proffered Paper session – Supportive and palliative care Q&A 2 (Video MP4 Format)
Proffered Paper session – Supportive and palliative care Q&A 2 (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research 1206O – Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research 1206O – Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research 1207O – Beyond 100,000 genomes project- Whole genome sequencing for cancer patients within NHS Genomic Medicine Service (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research 1207O – Beyond 100,000 genomes project- Whole genome sequencing for cancer patients within NHS Genomic Medicine Service (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research 2231O – Pan-cancer assessment of the impact of intronic variants on cancer development and progression (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research 2231O – Pan-cancer assessment of the impact of intronic variants on cancer development and progression (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant 1207O and 2231O (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant 1207O and 2231O (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant LBA55, 1206O and LBA16 (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant LBA55, 1206O and LBA16 (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research LBA16 – Primary analysis of efficacy and safety in the CUPISCO trial- A randomised, global study of targeted (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research LBA16 – Primary analysis of efficacy and safety in the CUPISCO trial- A randomised, global study of targeted (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research LBA55 – An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research LBA55 – An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer (PDF Format)
Proffered Paper session 1 – Basic Science and Translational research Q&A 1 (Video MP4 Format)
Proffered Paper session 1 – Basic Science and Translational research Q&A 2 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 549O – Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC) (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 549O – Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC) (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 550O – Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC) (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 550O – Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC) (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 551O – Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 551O – Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant 549O, 550O and 551O (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant 549O, 550O and 551O (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant LBA25 and LBA26 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant LBA25 and LBA26 (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA25 – Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA25 – Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA26 – Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA26 – Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Q&A 1 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Q&A 2 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive 1511O – Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive 1511O – Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 1511O (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 1511O (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA74 and LBA73 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA74 and LBA73 (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA75 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA75 (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA73 – Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA73 – Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA74 – Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA74 – Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA75 – Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA75 – Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal (PDF Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Q&A 1 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Q&A 2 (Video MP4 Format)
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Q&A 3 (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2359O – Phase III THOR study- Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2359O – Phase III THOR study- Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (PDF Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2360O – The double antibody drug conjugate (DAD) phase I trial- Sacituzumab govitecan (SG) plus enfortumab (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2360O – The double antibody drug conjugate (DAD) phase I trial- Sacituzumab govitecan (SG) plus enfortumab (PDF Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2359O and LBA102 (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2359O and LBA102 (PDF Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2360O and LBA103 (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2360O and LBA103 (PDF Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA102 – THOR-2 cohort 1- Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA102 – THOR-2 cohort 1- Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) (PDF Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA103 – ICRA- Efficacy of paclitaxel with tremelimumab +- durvalumab in metastatic urothelial carcinoma after (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA103 – ICRA- Efficacy of paclitaxel with tremelimumab +- durvalumab in metastatic urothelial carcinoma after (PDF Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate Q&A 1 (Video MP4 Format)
Proffered Paper session 1 – Genitourinary tumours, non-prostate Q&A 2 (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA36 and LBA37 (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA36 and LBA37 (PDF Format)
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA38 (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA38 (PDF Format)
Proffered Paper session 1 – Gynaecological cancers LBA36 – Efficacy and safety of senaparib as maintenance treatment in patients with newly (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers LBA36 – Efficacy and safety of senaparib as maintenance treatment in patients with newly (PDF Format)
Proffered Paper session 1 – Gynaecological cancers LBA37 – Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers LBA37 – Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for (PDF Format)
Proffered Paper session 1 – Gynaecological cancers LBA38 – Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers LBA38 – Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer (PDF Format)
Proffered Paper session 1 – Gynaecological cancers Q&A 1 (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers Q&A 1 (PDF Format)
Proffered Paper session 1 – Gynaecological cancers Q&A 2 (Video MP4 Format)
Proffered Paper session 1 – Gynaecological cancers Q&A 2 (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research 131O – A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research 131O – A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research 1O – CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research 1O – CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research 2232O – Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research 2232O – Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research 2O – PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1+ T cells with implications for cancer immunotherapy (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research 2O – PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1+ T cells with implications for cancer immunotherapy (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research 3O – IGSF8 is an innate immune checkpoint and cancer immunotherapy target (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research 3O – IGSF8 is an innate immune checkpoint and cancer immunotherapy target (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 131O and 1O (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 131O and 1O (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 2232O, 2O and 3O (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 2232O, 2O and 3O (PDF Format)
Proffered Paper session 2 – Basic Science and Translational research Q&A 1 (Video MP4 Format)
Proffered Paper session 2 – Basic Science and Translational research Q&A 2 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 552O – FOxTROT- Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 552O – FOxTROT- Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 553O – Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 553O – Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 552O and LBA27 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 552O and LBA27 (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 553O, LBA28 and LBA29 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 553O, LBA28 and LBA29 (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA27 – First-line systemic treatment in patients with initially unresectable colorectal cancer liver (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA27 – First-line systemic treatment in patients with initially unresectable colorectal cancer liver (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA28 – The PEGASUS trial- Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA28 – The PEGASUS trial- Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA29 – Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT)- An international, phase III (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA29 – Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT)- An international, phase III (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Q&A 1 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Q&A 2 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive 1616O – Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive 1616O – Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant 1616O and LBA83 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant 1616O and LBA83 (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant LBA76 and LBA77 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant LBA76 and LBA77 (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA76 – The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA76 – The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA77 – 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA77 – 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA83 – Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA83 – Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based (PDF Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Q&A 1 (Video MP4 Format)
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Q&A 2 (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1881O – Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC- Results of the (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1881O – Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC- Results of the (PDF Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1882O – RENOTORCH- Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1882O – RENOTORCH- Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced (PDF Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant 1882O (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant 1882O (PDF Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant LBA87, LBA88 and 1881O (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant LBA87, LBA88 and 1881O (PDF Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA87 – Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA87 – Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell (PDF Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA88 – Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA88 – Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal (PDF Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate Q&A 1 (Video MP4 Format)
Proffered Paper session 2 – Genitourinary tumours, non-prostate Q&A 2 (Video MP4 Format)
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA40 (Video MP4 Format)
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA40 (PDF Format)
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA41 and LBA42 (Video MP4 Format)
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA41 and LBA42 (PDF Format)
Proffered Paper session 2 – Gynaecological cancers LBA40 – Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with (Video MP4 Format)
Proffered Paper session 2 – Gynaecological cancers LBA40 – Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with (PDF Format)
Proffered Paper session 2 – Gynaecological cancers LBA41 – Durvalumab (durva) plus carboplatin paclitaxel (CP) followed by maintenance (mtx) durva ñ olaparib (Video MP4 Format)
Proffered Paper session 2 – Gynaecological cancers LBA41 – Durvalumab (durva) plus carboplatin paclitaxel (CP) followed by maintenance (mtx) durva ñ olaparib (PDF Format)
Proffered Paper session 2 – Gynaecological cancers Q&A 1 (Video MP4 Format)
Proffered Paper session 2 – Gynaecological cancers Q&A 2 (Video MP4 Format)
Proffered paper session Policy and preventive strategies 1687O – PRIMCAT- A novel approach to informing health technology assessment decision making in Australia (Video MP4 Format)
Proffered paper session Policy and preventive strategies 1687O – PRIMCAT- A novel approach to informing health technology assessment decision making in Australia (PDF Format)
Proffered paper session Policy and preventive strategies 1688O – Informative censoring of surrogate end-point data in FDA-approved cancer drugs (Video MP4 Format)
Proffered paper session Policy and preventive strategies 1688O – Informative censoring of surrogate end-point data in FDA-approved cancer drugs (PDF Format)
Proffered paper session Policy and preventive strategies 1689O – Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in (Video MP4 Format)
Proffered paper session Policy and preventive strategies 1689O – Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in (PDF Format)
Proffered paper session Policy and preventive strategies 1690O – Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer (Video MP4 Format)
Proffered paper session Policy and preventive strategies 1690O – Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer (PDF Format)
Proffered paper session Policy and preventive strategies 1691O – Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre (Video MP4 Format)
Proffered paper session Policy and preventive strategies 1691O – Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre (PDF Format)
Proffered paper session Policy and preventive strategies Invited Discussant 1687O, 1688O and 1689O (Video MP4 Format)
Proffered paper session Policy and preventive strategies Invited Discussant 1687O, 1688O and 1689O (PDF Format)
Proffered paper session Policy and preventive strategies Invited Discussant 1690O and 1691O (Video MP4 Format)
Proffered paper session Policy and preventive strategies Invited Discussant 1690O and 1691O (PDF Format)
Proffered paper session Policy and preventive strategies Q&A 1 (Video MP4 Format)
Proffered paper session Policy and preventive strategies Q&A 2 (Video MP4 Format)
Protein degrading cancer drugs- The promises of the new generation Bifunctional small molecules that mediate the degradation of extracellular proteins (Video MP4 Format)
Protein degrading cancer drugs- The promises of the new generation Bifunctional small molecules that mediate the degradation of extracellular proteins (PDF Format)
Protein degrading cancer drugs- The promises of the new generation Conclusions and perspectives (Video MP4 Format)
Protein degrading cancer drugs- The promises of the new generation Degrading cancer targets on the cell surface (SureTACs) (Video MP4 Format)
Protein degrading cancer drugs- The promises of the new generation Degrading oncogenic transcription factors (Video MP4 Format)
Protein degrading cancer drugs- The promises of the new generation Degrading oncogenic transcription factors (PDF Format)
Protein degrading cancer drugs- The promises of the new generation Discussion (Video MP4 Format)
Protein degrading cancer drugs- The promises of the new generation Discussion (PDF Format)
Protein degrading cancer drugs- The promises of the new generation Introduction and scientific background (Video MP4 Format)
Rectal cancer with oligometastatic disease Case condition presentation (Video MP4 Format)
Rectal cancer with oligometastatic disease Case condition presentation (PDF Format)
Rectal cancer with oligometastatic disease Discussion (Video MP4 Format)
Rectal cancer with oligometastatic disease Discussion (PDF Format)
Rectal cancer with oligometastatic disease How to perform an accurate staging (Video MP4 Format)
Rectal cancer with oligometastatic disease How to perform an accurate staging (PDF Format)
Rectal cancer with oligometastatic disease Options for the choice of the systemic therapy (Video MP4 Format)
Rectal cancer with oligometastatic disease Options for the choice of the systemic therapy (PDF Format)
Rectal cancer with oligometastatic disease Radiotherapy and timing (Video MP4 Format)
Rectal cancer with oligometastatic disease Radiotherapy and timing (PDF Format)
Rectal cancer with oligometastatic disease Timing and modality of surgical intervention (Video MP4 Format)
Rectal cancer with oligometastatic disease Timing and modality of surgical intervention (PDF Format)
Relieving complex suffering in women with advanced cervical cancer Discussion (Video MP4 Format)
Relieving complex suffering in women with advanced cervical cancer Discussion (PDF Format)
Relieving complex suffering in women with advanced cervical cancer Nausea and vomiting in advanced cervical cancer (Video MP4 Format)
Relieving complex suffering in women with advanced cervical cancer Nausea and vomiting in advanced cervical cancer (PDF Format)
Relieving complex suffering in women with advanced cervical cancer Presentation of case condition (Video MP4 Format)
Relieving complex suffering in women with advanced cervical cancer Presentation of case condition (PDF Format)
Relieving complex suffering in women with advanced cervical cancer Refractory pain (Video MP4 Format)
Relieving complex suffering in women with advanced cervical cancer Refractory pain (PDF Format)
Relieving complex suffering in women with advanced cervical cancer Ureteral and bowel obstruction, haemorrhage- A surgical perspective (Video MP4 Format)
Relieving complex suffering in women with advanced cervical cancer Ureteral and bowel obstruction, haemorrhage- A surgical perspective (PDF Format)
Scientific Congress Highlights 1 Basic science & translational research (Video MP4 Format)
Scientific Congress Highlights 1 Basic science & translational research (PDF Format)
Scientific Congress Highlights 1 Breast cancer, early stage (Video MP4 Format)
Scientific Congress Highlights 1 Breast cancer, early stage (PDF Format)
Scientific Congress Highlights 1 Breast cancer, metastatic (Video MP4 Format)
Scientific Congress Highlights 1 Breast cancer, metastatic (PDF Format)
Scientific Congress Highlights 1 CNS tumours (Video MP4 Format)
Scientific Congress Highlights 1 CNS tumours (PDF Format)
Scientific Congress Highlights 1 Developmental therapeutics (Video MP4 Format)
Scientific Congress Highlights 1 Developmental therapeutics (PDF Format)
Scientific Congress Highlights 1 GU non-prostate (Video MP4 Format)
Scientific Congress Highlights 1 GU non-prostate (PDF Format)
Scientific Congress Highlights 1 GU prostate (Video MP4 Format)
Scientific Congress Highlights 1 GU prostate (PDF Format)
Scientific Congress Highlights 1 Gynaecological cancers (Video MP4 Format)
Scientific Congress Highlights 1 Gynaecological cancers (PDF Format)
Scientific Congress Highlights 1 Investigational immunotherapy (Video MP4 Format)
Scientific Congress Highlights 1 Investigational immunotherapy (PDF Format)
Scientific Congress Highlights 1 Policy and preventive strategies (Video MP4 Format)
Scientific Congress Highlights 1 Policy and preventive strategies (PDF Format)
Scientific Congress Highlights 2 GI, lower digestive (Video MP4 Format)
Scientific Congress Highlights 2 GI, lower digestive (PDF Format)
Scientific Congress Highlights 2 GI, upper digestive- Gastroesophageal (Video MP4 Format)
Scientific Congress Highlights 2 GI, upper digestive- Gastroesophageal (PDF Format)
Scientific Congress Highlights 2 GI, upper digestive- HPB (Video MP4 Format)
Scientific Congress Highlights 2 GI, upper digestive- HPB (PDF Format)
Scientific Congress Highlights 2 Haematological malignancies (Video MP4 Format)
Scientific Congress Highlights 2 Haematological malignancies (PDF Format)
Scientific Congress Highlights 2 Head and neck cancer (Video MP4 Format)
Scientific Congress Highlights 2 Head and neck cancer (PDF Format)
Scientific Congress Highlights 2 Melanoma and other skin tumours (Video MP4 Format)
Scientific Congress Highlights 2 Melanoma and other skin tumours (PDF Format)
Scientific Congress Highlights 2 NETs and endocrine tumours (Video MP4 Format)
Scientific Congress Highlights 2 NETs and endocrine tumours (PDF Format)
Scientific Congress Highlights 2 Non-metastatic NSCLC and other thoracic malignancies (Video MP4 Format)
Scientific Congress Highlights 2 Non-metastatic NSCLC and other thoracic malignancies (PDF Format)
Scientific Congress Highlights 2 NSCLC, metastatic (Video MP4 Format)
Scientific Congress Highlights 2 NSCLC, metastatic (PDF Format)
Scientific Congress Highlights 2 Sarcoma (Video MP4 Format)
Scientific Congress Highlights 2 Sarcoma (PDF Format)
Scientific Congress Highlights 2 Supportive and palliative care (Video MP4 Format)
Scientific Congress Highlights 2 Supportive and palliative care (PDF Format)
Seagen – ADCs’ Potential Across Tumors ADC Technologies in Oncology (Video MP4 Format)
Seagen – ADCs’ Potential Across Tumors Advances in ADCs for Head and Neck Cancer (Video MP4 Format)
Seagen – ADCs’ Potential Across Tumors Closing Remarks (Video MP4 Format)
Seagen – ADCs’ Potential Across Tumors Emerging ADCs in Non-Small Cell Lung Cancer (Video MP4 Format)
Seagen – ADCs’ Potential Across Tumors Future Directions for ADCs in Urothelial Cancer (Video MP4 Format)
Seagen – ADCs’ Potential Across Tumors Panel Discussion and Audience Q&A (Video MP4 Format)
Seagen – ADCs’ Potential Across Tumors Welcome and Introduction (Video MP4 Format)
Seagen – Case by Case- Strategic Sequencing Considerations Charting the Course- Navigating the Landscape From Real-world Evidence to Future Studies (Video MP4 Format)
Seagen – Case by Case- Strategic Sequencing Considerations Closing Remarks (Video MP4 Format)
Seagen – Case by Case- Strategic Sequencing Considerations Decision-making in 3L Following T-DXd Progression (Case-based discussion) (Video MP4 Format)
Seagen – Case by Case- Strategic Sequencing Considerations Decision-making in 3L Progression With CNS Involvement (Case-based discussion) (Video MP4 Format)
Seagen – Case by Case- Strategic Sequencing Considerations Embracing Change- Uncovering Challenges and Opportunities in the Changing Treatment Landscape of HER2+ MBC (Video MP4 Format)
Seagen – Case by Case- Strategic Sequencing Considerations Q&A (Video MP4 Format)
Seagen – Case by Case- Strategic Sequencing Considerations Welcome and Introductions (Video MP4 Format)
Seagen – HER2-Targeted Therapies in mCRC Closing Remarks (Video MP4 Format)
Seagen – HER2-Targeted Therapies in mCRC Exploring New Opportunities to Improve Outcomes in Patients with HER2+ mCRC (Video MP4 Format)
Seagen – HER2-Targeted Therapies in mCRC HER2 as an Actionable Target in HER2+ mCRC (Video MP4 Format)
Seagen – HER2-Targeted Therapies in mCRC Panel Discussion and Interactive Q&A (Video MP4 Format)
Seagen – HER2-Targeted Therapies in mCRC The Role of HER2 Testing in mCRC (Video MP4 Format)
Seagen – HER2-Targeted Therapies in mCRC Welcome and Introduction (Video MP4 Format)
Servier – A journey through IDH1mutated Cholangiocarcinoma CCA diagnosis- current practice and challenges (Video MP4 Format)
Servier – A journey through IDH1mutated Cholangiocarcinoma Conclusion (Video MP4 Format)
Servier – A journey through IDH1mutated Cholangiocarcinoma Introducing a patient case with IDH1 mutated CCA (Video MP4 Format)
Servier – A journey through IDH1mutated Cholangiocarcinoma Introduction (Video MP4 Format)
Servier – A journey through IDH1mutated Cholangiocarcinoma Molecular profiling in CCA- where do we stand. (Video MP4 Format)
Servier – A journey through IDH1mutated Cholangiocarcinoma Panel discussion Q&A (Video MP4 Format)
Servier – A journey through IDH1mutated Cholangiocarcinoma Treatment landscape in CCA and future perspectives (Video MP4 Format)
Servier – Are brain cancer patients finally able to Connecting the dots- Understanding recent clinical evidence in the framework of previous studies and current practice (Video MP4 Format)
Servier – Are brain cancer patients finally able to IDH Mutated Glioma- A Decade’s journey from bench to bedside (Video MP4 Format)
Servier – Are brain cancer patients finally able to Introduction- The Sword of Damocles hanging over each patient (Video MP4 Format)
Servier – Are brain cancer patients finally able to Navigating the paradigm shift- Thriving in the new era glioma care (Video MP4 Format)
Servier – Are brain cancer patients finally able to The evolving paradigm for clinical management of glioma (Video MP4 Format)
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Conclusion (Video MP4 Format)
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Introduction (Video MP4 Format)
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC New approaches in treating patients with mCRC (Video MP4 Format)
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Patient cases in mCRC and panel discussion (Video MP4 Format)
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Redefining the meaning of later lines of therapy (Video MP4 Format)
Tertiary lymphoid structures- The control centre of immune responses against tumors Discussion led by Chair (Video MP4 Format)
Tertiary lymphoid structures- The control centre of immune responses against tumors Discussion led by Chair (PDF Format)
Tertiary lymphoid structures- The control centre of immune responses against tumors Presentation by Expert (Video MP4 Format)
Tertiary lymphoid structures- The control centre of immune responses against tumors Presentation by Expert (PDF Format)
The hallmarks of cancer in 2023 Introduction by the Chair (Video MP4 Format)
The hallmarks of cancer in 2023 Introduction by the Chair (PDF Format)
The hallmarks of cancer in 2023 The hallmarks of cancer in 2023 (Video MP4 Format)
The hallmarks of cancer in 2023 The hallmarks of cancer in 2023 (PDF Format)
The importance of secondary prevention Cancer screening, another ground of health equity (Video MP4 Format)
The importance of secondary prevention Cancer screening, another ground of health equity (PDF Format)
The importance of secondary prevention Discussion (Video MP4 Format)
The importance of secondary prevention Discussion (PDF Format)
The importance of secondary prevention Improving early diagnosis through screening programme guidelines- The case of lung cancer (Video MP4 Format)
The importance of secondary prevention Improving early diagnosis through screening programme guidelines- The case of lung cancer (PDF Format)
The importance of secondary prevention The case of colon cancer (Video MP4 Format)
The importance of secondary prevention The case of colon cancer (PDF Format)
The importance of secondary prevention The case of dental screening programmes (Video MP4 Format)
The importance of secondary prevention The case of dental screening programmes (PDF Format)
The importance of secondary prevention The importance of harmonizing screening programmes across different levels of healthcare systems- Europe, national, regional (Video MP4 Format)
The importance of secondary prevention The importance of harmonizing screening programmes across different levels of healthcare systems- Europe, national, regional (PDF Format)
The importance to address the caregivers needs Cancer patient groups and their help to support caregivers- Guide for healthcare professionals (Video MP4 Format)
The importance to address the caregivers needs Cancer patient groups and their help to support caregivers- Guide for healthcare professionals (PDF Format)
The importance to address the caregivers needs Caregiver Carer Who are they (Video MP4 Format)
The importance to address the caregivers needs Caregiver Carer Who are they (PDF Format)
The importance to address the caregivers needs Caregivers after patient end of life- The caregivers’ role continues.as do their needs! (Video MP4 Format)
The importance to address the caregivers needs Caregivers after patient end of life- The caregivers’ role continues.as do their needs! (PDF Format)
The importance to address the caregivers needs Caregivers’ needs along the patient journey- What do nurses need to know. (Video MP4 Format)
The importance to address the caregivers needs Caregivers’ needs along the patient journey- What do nurses need to know. (PDF Format)
The importance to address the caregivers needs Caregivers’ needs along the patient journey- What do oncologists need to know. (Video MP4 Format)
The importance to address the caregivers needs Conclusion (Video MP4 Format)
The importance to address the caregivers needs Discussion (Video MP4 Format)
The importance to address the caregivers needs Discussion (PDF Format)
The positive sentinel lymph node- What does it mean for treatment A medical oncologist’s perspective (Video MP4 Format)
The positive sentinel lymph node- What does it mean for treatment A medical oncologist’s perspective (PDF Format)
The positive sentinel lymph node- What does it mean for treatment A radiation oncologist’s perspective (Video MP4 Format)
The positive sentinel lymph node- What does it mean for treatment A radiation oncologist’s perspective (PDF Format)
The positive sentinel lymph node- What does it mean for treatment A surgeon’s perspective (Video MP4 Format)
The positive sentinel lymph node- What does it mean for treatment A surgeon’s perspective (PDF Format)
The positive sentinel lymph node- What does it mean for treatment Discussion (Video MP4 Format)
The positive sentinel lymph node- What does it mean for treatment Discussion (PDF Format)
Therapeutic view on tumour immune microenvironment- It’s TIME How tumour-draining lymph nodes inform the content of the TME and vice versa (Video MP4 Format)
Therapeutic view on tumour immune microenvironment- It’s TIME How tumour-draining lymph nodes inform the content of the TME and vice versa (PDF Format)
Therapeutic view on tumour immune microenvironment- It’s TIME Immune suppressive cell populations in TME (Video MP4 Format)
Therapeutic view on tumour immune microenvironment- It’s TIME Immune suppressive cell populations in TME (PDF Format)
Therapeutic view on tumour immune microenvironment- It’s TIME Modulating TME to overcome primary and acquired resistance (Video MP4 Format)
Therapeutic view on tumour immune microenvironment- It’s TIME Modulating TME to overcome primary and acquired resistance (PDF Format)
Therapeutic view on tumour immune microenvironment- It’s TIME Q&A and Discussion (Video MP4 Format)
Therapeutic view on tumour immune microenvironment- It’s TIME Q&A and Discussion (PDF Format)
Transnational cancer policies EBCP and implementation plans at the EU level (Video MP4 Format)
Transnational cancer policies EBCP and implementation plans at the EU level (PDF Format)
Transnational cancer policies Q&A and Discussion (Video MP4 Format)
Transnational cancer policies Q&A and Discussion (PDF Format)
Transnational cancer policies The joint development of policies through Joint Actions as policy projects, and the arising EU guide for National Cancer Control Programmes (Video MP4 Format)
Transnational cancer policies The joint development of policies through Joint Actions as policy projects, and the arising EU guide for National Cancer Control Programmes (PDF Format)
Transnational cancer policies The Youth Cancer Europe’s perspective (Video MP4 Format)
Transnational cancer policies The Youth Cancer Europe’s perspective (PDF Format)
Transnational cancer policies WHO IARC national cancer control plan tool and case studies (Video MP4 Format)
Transnational cancer policies WHO IARC national cancer control plan tool and case studies (PDF Format)
Unravelling choices for adjuvant endocrine therapy Beyond chemo and endocrine therapy (Video MP4 Format)
Unravelling choices for adjuvant endocrine therapy Beyond chemo and endocrine therapy (PDF Format)
Unravelling choices for adjuvant endocrine therapy ER positive breast cancer- What endocrine therapy is needed in menopausal patients (Video MP4 Format)
Unravelling choices for adjuvant endocrine therapy ER positive breast cancer- What endocrine therapy is needed in menopausal patients (PDF Format)
Unravelling choices for adjuvant endocrine therapy Q&A and Discussion (Video MP4 Format)
Unravelling choices for adjuvant endocrine therapy Q&A and Discussion (PDF Format)
Unravelling choices for adjuvant endocrine therapy Risk assessment stratification (Video MP4 Format)
Unravelling choices for adjuvant endocrine therapy Risk assessment stratification (PDF Format)
Upper GI cancers- From bench to bedside Conclusions and perspectives (Video MP4 Format)
Upper GI cancers- From bench to bedside ctDNA- From theory to clinical translation (Video MP4 Format)
Upper GI cancers- From bench to bedside ctDNA- From theory to clinical translation (PDF Format)
Upper GI cancers- From bench to bedside Discussion (Video MP4 Format)
Upper GI cancers- From bench to bedside Discussion (PDF Format)
Upper GI cancers- From bench to bedside Evolving diagnostics in gastroesophageal cancer (Video MP4 Format)
Upper GI cancers- From bench to bedside Evolving diagnostics in gastroesophageal cancer (PDF Format)
Upper GI cancers- From bench to bedside Heterogeneity, evolution, and outcomes in gastroesophageal cancer (Video MP4 Format)
Upper GI cancers- From bench to bedside Heterogeneity, evolution, and outcomes in gastroesophageal cancer (PDF Format)
Upper GI cancers- From bench to bedside Introduction and scientific background (Video MP4 Format)
Upper GI cancers- From bench to bedside Introduction and scientific background (PDF Format)
Upper GI cancers- From bench to bedside New directions in pancreas cancer (Video MP4 Format)
Upper GI cancers- From bench to bedside New directions in pancreas cancer (PDF Format)
What is the optimal therapeutic approach following Discussion (Video MP4 Format)
What is the optimal therapeutic approach following Discussion (PDF Format)
What is the optimal therapeutic approach following Novel treatment options for PARPi resistant ovarian cancer (Video MP4 Format)
What is the optimal therapeutic approach following Novel treatment options for PARPi resistant ovarian cancer (PDF Format)
What is the optimal therapeutic approach following Presentation of case condition (Video MP4 Format)
What is the optimal therapeutic approach following Presentation of case condition (PDF Format)
What is the optimal therapeutic approach following Systemic treatment options following progression on PARPi (Video MP4 Format)
What is the optimal therapeutic approach following Systemic treatment options following progression on PARPi (PDF Format)
What is the optimal therapeutic approach following The role of surgery (Video MP4 Format)
What is the optimal therapeutic approach following The role of surgery (PDF Format)
What is the optimal therapeutic approach following Understanding and overcoming resistance to PARP inhibitors- What is the way forward (Video MP4 Format)
What is the optimal therapeutic approach following Understanding and overcoming resistance to PARP inhibitors- What is the way forward (PDF Format)
What’s the future in melanoma therapy Bispecific T-Cell engagers (TCE) and fusion protein carriers- Ready for prime-time in melanoma. (Video MP4 Format)
What’s the future in melanoma therapy Bispecific T-Cell engagers (TCE) and fusion protein carriers- Ready for prime-time in melanoma. (PDF Format)
What’s the future in melanoma therapy Clinical data, NGS, (x)-omics et al.- What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors (Video MP4 Format)
What’s the future in melanoma therapy Clinical data, NGS, (x)-omics et al.- What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors (PDF Format)
What’s the future in melanoma therapy Conclusions and perspectives (Video MP4 Format)
What’s the future in melanoma therapy Conclusions and perspectives (PDF Format)
What’s the future in melanoma therapy Discussion (Video MP4 Format)
What’s the future in melanoma therapy Discussion (PDF Format)
What’s the future in melanoma therapy Introduction and scientific background (Video MP4 Format)
What’s the future in melanoma therapy Introduction and scientific background (PDF Format)
What’s the future in melanoma therapy Revisiting old friends New clinical developments of MEKi BRAFi NRASi combinations (Video MP4 Format)
What’s the future in melanoma therapy Revisiting old friends New clinical developments of MEKi BRAFi NRASi combinations (PDF Format)
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Discussion led by Chair (Video MP4 Format)
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Discussion led by Chair (PDF Format)
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Presentation by Expert (Video MP4 Format)
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Presentation by Expert (PDF Format)
When can we cure patients with metastatic sarcoma Discussion led by Chair (Video MP4 Format)
When can we cure patients with metastatic sarcoma Introduction (Video MP4 Format)
When can we cure patients with metastatic sarcoma Introduction (PDF Format)
When can we cure patients with metastatic sarcoma Presentation by Expert (Video MP4 Format)
When can we cure patients with metastatic sarcoma Presentation by Expert (PDF Format)
When does targeted therapy outperform immunotherapy in patients with advanced melanoma Discussion led by Chair (Video MP4 Format)
When does targeted therapy outperform immunotherapy in patients with advanced melanoma Presentation by Expert (Video MP4 Format)
When does targeted therapy outperform immunotherapy in patients with advanced melanoma Presentation by Expert (PDF Format)
When to stop systemic anticancer treatment in patients with advanced malignancy Discussion led by Chair (Video MP4 Format)
When to stop systemic anticancer treatment in patients with advanced malignancy Discussion led by Chair (PDF Format)
When to stop systemic anticancer treatment in patients with advanced malignancy Presentation by Expert (Video MP4 Format)
When to stop systemic anticancer treatment in patients with advanced malignancy Presentation by Expert (PDF Format)
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause 10 years of ESMO W4O advocating for gender equity (Video MP4 Format)
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause 10 years of ESMO W4O advocating for gender equity (PDF Format)
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause Live discussion, Q&A and wrap-up (Video MP4 Format)
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause Welcome (Video MP4 Format)
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause Welcome (PDF Format)
YO Boxing session Discussion led by Chairs 1 (Video MP4 Format)
YO Boxing session Discussion led by Chairs 1 (PDF Format)
YO Boxing session Discussion led by Chairs 2 (Video MP4 Format)
YO Boxing session Discussion led by Chairs 2 (PDF Format)
YO Boxing session Do you need a basic science rotation for your career in oncology. No (Video MP4 Format)
YO Boxing session Do you need a basic science rotation for your career in oncology. No (PDF Format)
YO Boxing session Do you need a basic science rotation for your career in oncology. Yes (Video MP4 Format)
YO Boxing session Do you need a basic science rotation for your career in oncology. Yes (PDF Format)
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – No (Video MP4 Format)
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – No (PDF Format)
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – Yes (Video MP4 Format)
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – Yes (PDF Format)
YO Brunch 1- Caring for the LGBTQ+ cancer patient Discussion led by Chair (Video MP4 Format)
YO Brunch 1- Caring for the LGBTQ+ cancer patient Discussion led by Chair (PDF Format)
YO Brunch 1- Caring for the LGBTQ+ cancer patient (Video MP4 Format)
YO Brunch 1- Caring for the LGBTQ+ cancer patient (PDF Format)
YO Brunch 2- How to tell a compelling story in scientific articles and presentations Discussion led by Chair (Video MP4 Format)
YO Brunch 2- How to tell a compelling story in scientific articles and presentations Discussion led by Chair (PDF Format)
YO Brunch 2- How to tell a compelling story in scientific articles and presentations (Video MP4 Format)
YO Brunch 2- How to tell a compelling story in scientific articles and presentations (PDF Format)
YO Brunch 3- Establishing successful global research collaborations and network Discussion led by Chair (PDF Format)
YO Brunch 3- Establishing successful global research collaborations and network (Video MP4 Format)
YO Brunch 3- Establishing successful global research collaborations and network (PDF Format)
YO Clinical Case Discussion sessions Table 2- Integration of liquid biopsy in decision making in the management of patients with colon cancer (PDF Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Awards- Presentation of the 2023 Fellows and Best Exam (Video MP4 Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Awards- Presentation of the 2023 Fellows and Best Exam (PDF Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Fellowship Project (Video MP4 Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Fellowship Project (PDF Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Publication from a Fellowship (Video MP4 Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Publication from a Fellowship (PDF Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Conclusions (Video MP4 Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Conclusions (PDF Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Introduction to the ESMO Fellowship Programme (Video MP4 Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Introduction to the ESMO Fellowship Programme (PDF Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Practical tips from a former fellow (Video MP4 Format)
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Practical tips from a former fellow (PDF Format)
YO Forum- Preparing future-proof (young) oncologists Discussion (Video MP4 Format)
YO Forum- Preparing future-proof (young) oncologists Discussion (PDF Format)
YO Forum- Preparing future-proof (young) oncologists Empowerment and resilience- A toolbox to foster your well-being and personal development (Video MP4 Format)
YO Forum- Preparing future-proof (young) oncologists Empowerment and resilience- A toolbox to foster your well-being and personal development (PDF Format)
YO Forum- Preparing future-proof (young) oncologists How to put together a great CV and make a standout application (Video MP4 Format)
YO Forum- Preparing future-proof (young) oncologists How to put together a great CV and make a standout application (PDF Format)
YO Forum- Preparing future-proof (young) oncologists How to write a successful research grant protocol (Video MP4 Format)
YO Forum- Preparing future-proof (young) oncologists How to write a successful research grant protocol (PDF Format)
YO Forum- Preparing future-proof (young) oncologists The dos and don’ts of research project management (Video MP4 Format)
YO Forum- Preparing future-proof (young) oncologists The dos and don’ts of research project management (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Bridging the gap between basic science and clinical research (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Bridging the gap between basic science and clinical research (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 1 (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 1 (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 2 (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 2 (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 3 (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 3 (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 4 (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Discussion 4 (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Interpreting clinical trial data- How to understand subgroup analyses (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Interpreting clinical trial data- How to understand subgroup analyses (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Investigator-initiated trials- From design to activation (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Investigator-initiated trials- From design to activation (PDF Format)
YO Masterclass- Tackling new challenges facing young investigators Preprints from medRxiv and bioRxiv- Should I trust them (Video MP4 Format)
YO Masterclass- Tackling new challenges facing young investigators Preprints from medRxiv and bioRxiv- Should I trust them (PDF Format)